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Executive Summary 
 
This study was designed to review the progress and on-going 
challenges of implementing HIV/AIDS policy in the CGIAR. The 
study rests on three foundations:  (1) a survey of HIV/AIDS policy 
implementation at all 16 Future Harvest Centers; (2) a case study of 
HIV/AIDS policy implementation in Kenya; and, (3) an exploration 
of insurance coverage for HIV/AIDS medical care.  
 
The study concludes that policy development has been sound.  Half of 
all Future Harvest Centers have developed an HIV/AIDS Workplace 
Policy.  There is strong commitment to the core principles of non-
discrimination and non-disclosure with regard to HIV status 
throughout the system. Implementation has been slow in the 
fundamental areas of education and prevention, including such 
concerns as encouragement of Voluntary Counseling and Testing 
(VCT), development of peer counseling programs, distribution of 
condoms, and staff training.  Most critically, Centers have made little 
progress in the urgent matter of medical coverage for HIV/AIDS 
treatment for nationally recruited staff (NRS).   
 
Meanwhile, the global pandemic rages on with no region immune 
from the personal, social and economic ravages of HIV/AIDS.  
Although sub-Saharan Africa continues to lead the grim statistics, the 
virus is now spreading rapidly in Asia where there are now equally dire 
predictions. 
 
On the positive front, the price of anti-retroviral drugs (ARVs) has 
dropped significantly in many developing countries, dramatically so in 
some countries in sub-Saharan Africa within the past year.  The drop 
in cost of ARVs has made HIV/AIDS treatment an affordable option 
for Future Harvest Centers. Moreover, evidence is building from 
international studies that investments in HIV/AIDS education and 
prevention and ARV therapy offer clear financial benefits to 
organizations.  Future Harvest Centers must consider what changes to 
medical schemes are necessary to make this option a reality for all 
nationally recruited staff.   
 
The study presents evidence that insurers in Africa may be responding 
to the reduction in ARV prices by improving coverage for HIV/AIDS 
treatment. Centers are encouraged to explore those options locally, but 
if they are not successful in that regard, the study also presents 
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indicative costs for supplemental self-insurance for HIV/AIDS, as well 
as international insurance coverage secured on the basis of regional or 
inter-regional pooling.  These latter options, while considerably more 
expensive than many medical plans now in place, offer HIV/AIDS 
coverage absent from many current plans. 
 
Finally, the study recommends that all Centers continue to take an 
active interest in the continuing development of HIV/AIDS policy and 
practice, as the environment for HIV/AIDS prevention and care is 
changing rapidly, both locally and internationally.  All Centers, 
regardless of location, must pay closer attention to the HIV/AIDS 
education and care being extended by host institutions to their Africa- 
and Asia-based staff as they cannot safely assume that HIV/AIDS care 
is being fully managed on their behalf.  All Centers must engage in an 
accelerated and concentrated effort to implement HIV/AIDS policy, 
especially with regard to HIV/AIDS education and prevention in such 
areas as VCT.  All Centers are encouraged to localize HIV/AIDS 
Policy in very concrete terms with specific information regarding 
availability and cost of ARVs, identification of vetted VCT Clinics, 
sources of post-exposure prophylaxis (PEP) kits and lists of locations for 
safe blood. 
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Introduction 
 
Another one among us has died of AIDS.  
 
In the course of this study, a confirmed case of AIDS resulted in the 
death of another Future Harvest colleague. It is almost certain that 
other employees have died of AIDS in the past year, but in the absence 
of consistent care for persons living with HIV/AIDS, Future Harvest 
Centers are unable or reluctant to say more than we ‘suspect he or she 
died of AIDS’ or ‘medical claims suggest that we have five other 
HIV/AIDS cases, or maybe as many as ten.’  For some, the 
uncertainty fuels heightened concern; for others the lack of certainty 
permits inattention. 
 
Exactly one year ago, in October 2001, the CGIAR Gender & 
Diversity Program put forward model guidelines for HIV/AIDS policy 
and practice as a resource to Future Harvest Centers.  Its goal was to 
encourage adoption of HIV/AIDS policies and programs, in order to: 
Prevent further HIV infection among all CGIAR 
employees and their family members; 
Preserve the lives of those employers and their family 
members currently infected with HIV/AIDS; 
Provide compassionate care for those employees and their 
family members suffering and dying from AIDS; 
Foster a workplace that does not discriminate on the basis 
of disease; and, 
Set an example of compassionate management of 
HIV/AIDS in the communities in which the CGIAR 
works. 
 
Progress on HIV/AIDS policy formulation in the CGIAR has been 
generally sound, but implementation of policy remains a challenge.  
 
Meanwhile, the global pandemic rages on with no region immune 
from the personal, social and economic ravages of HIV/AIDS.  Sub-
Saharan Africa continues to lead the grim statistics with more than 15 
million deaths, more than 12 million orphans, and HIV prevalence 
rates greater than 15% in much of East Africa, more than 30% in 
some countries in Southern Africa, and approaching double digits in a 
number of West African countries. 
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But Asia, where the virus is spreading the fastest, is rapidly becoming 
the focus of equally dire predictions.  Thailand has been on the 
HIV/AIDS map for a number of years already, with HIV/AIDS 
prevalence rates of about 2 percent, which equals one in 60 of all 
people, and one in 30 of all working people.1  In China, if current 
infection rates hold steady, 10 million people will be HIV-positive by 
2010.  In Indonesia, explosive rates of HIV/AIDS prevalence in 
particular sub-populations and geographic regions are sparking fear of 
very rapid diffusion of HIV infection in the general population. 2 
Indeed, patterns of HIV infection in Indonesia, Cambodia, and 
Vietnam are near textbook examples of HIV/AIDS epidemic 
diffusion.  In India, the description of HIV disease must account for 
large geographic differences with some states such as Maharashtra, 
Andhra Pradesh and Tamil Nadu now registering HIV rates over 
three percent in pregnant women, far exceeding the national average. 
In the Philippines where HIV/AIDS prevalence remains fortunately 
very low, concern is focused on risky behaviors that are almost certain 
to contribute to the eventual spread of HIV.3 
 
But there is some encouraging news. The price of anti-retroviral drugs 
(ARVs) has dropped significantly in many developing countries, 
dramatically so in sub-Saharan Africa.  Efforts at education and 
prevention are thought to be having positive impact at the national 
level in some countries in Africa, notably Senegal and Uganda. 
Further investment by development agencies in surveillance and 
intervention systems in Asia hold a glimmer of hope that the spread of 
the disease can be arrested before it reaches the disastrous levels now 
prevalent in Africa.  Finally, research into an HIV/AIDS vaccine 
continues.    
 
The HIV/AIDS pandemic is a pressing challenge for the CGIAR.  
HIV/AIDS affects the health of friends and colleagues, the quality of 
work, and ultimately, prosperity and development throughout the 
world. In light of these challenges, the CGIAR has established a  
                                                 
1 According to the Thailand Business Coalition on AIDS at 
http://europa.eu.int/comm/development/aids/html/n10305.htm, September 2002. 
2 In Bogor, Indonesia the home of CIFOR headquarters and a large ICRAF regional office, one study shows 
HIV infection rates among intravenous drug users (IDUs) at 25%.  A typical pattern of diffusion for the 
HIV virus is from IDUs to sex workers to the clients of sex workers and then into the general population. 
(MAP, October 2001) 
3 Data drawn from UNAIDS and Map, October 2001. 
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“Systemwide Initiative on the Impact of HIV/AIDS on Agriculture, 
Agricultural Research and Development” (SWIHA). The CGIAR 
Gender & Diversity program was asked to take the lead to address the 
problem of HIV/AIDS in the CGIAR workplace. The Gender& 
Diversity (G&D) program welcomed this challenge, not only because it 
is an issue of enormous global significance, but also because 
HIV/AIDS is having a disproportionate impact on nationally 
recruited staff, which poses a direct threat to the diversity G&D seeks 
to foster.  
 
In 2001, the G&D issued working paper 28 “HIV/AIDS in the 
CGIAR Workplace:  Model Policies and Practices”. Future Harvest 
Centers responded to the worldwide epidemic by establishing 
thoughtful and well-crafted policies on HIV/AIDS. This study was 
designed to review the progress in policy formulation, with a primary 
focus on the challenges of implementing HIV/AIDS policy. The study 
builds on three areas of investigation:  (1) a survey of HIV/AIDS 
policy implementation at all 16 Future Harvest Centers; (2) a case 
study of HIV/AIDS policy implementation in Kenya; and, (3) an 
exploration of insurance options for HIV/AIDS medical care.  
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G&D HIV/AIDS Survey Results 
 
As a foundation for this study, the CGIAR Gender & Diversity 
program conducted a survey of all 16 Future Harvest Centers.  The 
survey sought information in three different areas: (1) the status of 
HIV/AIDS workplace policy and implementation in the CGIAR; (2) 
estimates of HIV/AIDS incidence and impact; and, (3) information on 
insurance policies for nationally recruited staff.  Information on 
insurance was gathered to assess the existing circumstances for 
HIV/AIDS care and as a basis for further research on insurance 
options. 
 
STATUS OF HIV/AIDS WORKPLACE POLICY AND 
IMPLEMENTATION 
 
HIV/AIDS Workplace Policy 
8 Centers have established or drafted HIV/AIDS policies that are 
committed to: 
No testing for HIV/AIDS 
Hiring without regard to HIV status 
Confidentiality with regard to HIV status 
 
All Centers are honoring their commitments in these fundamental 
areas. 
 
 
Most Future Harvest Centers located in developing countries, have 
established, or are in the process of developing, an HIV/AIDS 
workplace policy.  Although most have been issued as stand-alone 
documents, a few Centers have incorporated them into human 
resources policy documents. Three Centers in developing countries 
appear to have no plans to issue an HIV/AIDS document, but they 
are notably headquartered in countries with relatively low HIV/AIDS 
prevalence, CIAT and CIP in Latin America and ICARDA in the 
Middle East.  Nonetheless, CIP, for example, has expressed strong 
concerns about HIV/AIDS workplace issues for its project and 
program staff located in Africa and has taken the important step of 
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naming an HIV/AIDS focal person based in Africa.  IFPRI, IPGRI 
and ISNAR have not instituted HIV/AIDS policies on the stated (or 
apparent) grounds that compliance with strong host country laws 
“obviates the need for a separate specific statement for HIV/AIDS.” 
In summary, exactly one-half of all Centers have developed an 
HIV/AIDS workplace policy. 
 
The process of policy formulation in many Centers has been highly 
participatory.  Almost all Centers have made use of G&D working 
paper no. 28 “HIV/AIDS in the CIGAR Workplace:  Model Policies 
and Practices,” in drafting their policies. 
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Job Access, Job Security and Principles of Non-Disclosure 
 
All of the Centers that have established an HIV/AIDS policy, as well 
as those who have submitted policies to their Boards, have made, or 
expect to make, strong policy commitments to non-discrimination and 
non-disclosure: 
Job Access – no pre-employment screening or testing for 
HIV/AIDS; 
Job Security – no employee will be terminated on the basis 
of his or her HIV status; and, 
Principles of Non-Disclosure -- knowledge of an employee’s 
HIV status will be treated in complete confidence. 
 
Table 1 summarizes these commitments. 
 
 
Table 1: Policy Commitment to Job Access, Job Security, and Non-
Disclosure 
 
 HIV/AIDS Policy Job Access Job Security Non-
Disclosure 
Africa     
IITA February 1999 Yes Yes Yes 
ICRAF May 2001 Yes Yes Yes 
ILRI January 2002 Yes Yes Yes 
WARDA Submitted to Board Yes Yes Yes 
Asia     
IRRI January 2001 Yes Yes Yes 
IWMI November 2001 Yes Yes Yes 
ICLARM Submitted to Board Yes Yes Yes 
Latin 
America 
    
CIMMYT January 2002 Yes Yes Yes 
 
 
Some Centers have had difficulty implementing the ‘job access’ clause, 
because they have been unable to find insurers who do not require 
HIV/AIDS testing.  These Centers have, nonetheless, demonstrated 
their commitment to non-discrimination by not endorsing the practice 
of testing, by refusing to the greatest extent possible knowledge of the 
test results, and finally, of course, by employing staff regardless of their 
HIV status.  Responses to questions regarding implementation of the 
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‘job security’ clause, as well as conversations at ICRAF and ILRI, 
indicate that CGIAR centers are honoring their commitment. 
  
Some Centers have faced the painful reality of watching an employee 
become disabled by AIDS. WARDA reports, for example, on the 
discreet attempt to place ill employees in “less-tasking assignments.”  
One respondent expressed concern that the commitments to ‘job 
access’ and ‘job security’ are, in effect, commitments to employing, or 
maintaining employment of people unable or unfit to perform their 
jobs. 4  It must be stressed that no HIV/AIDS policy document 
reviewed in the course of this study should be construed as making 
such a commitment.5 The sad reality in the current environment, 
however, is -- that when disability insurance will not pay because a 
person has AIDS, when hospitalization benefits run out and medical 
insurance does not cover in-home care -- that Centers have allowed 
dying employees to continue working at low levels of productivity, in 
order that they can support their families for as long as possible.  This 
is not a desirable outcome, either for the Center or for the employee. It 
is hoped that improved HIV/AIDS care in the future will allow a 
more dignified and less painful choice for individuals and Centers.  
                                                 
4 In the HIV/AIDS literature this is labeled as a ”fear of AIDS exceptionalism “ and expresses the concern 
that people with HIV/AIDS will be treated better than employees with other diseases. This not the intent of 
HIV/AIDS policy, nor is there any evidence from this study that that is happening. The fact remains that 
organizations need to acknowledge that HIV may be different from other diseases because the stigma it 
carries can compromise care. Additionally, the sheer numbers of employees that have or may develop 
HIV/AIDS suggests a specific, concentrated response by employers worldwide. 
5 Many HIV/AIDS policies are careful to state that HIV/AIDS will be “ treated like any other chronic 
disease” or “in the eventuality that an employee becomes disabled that he or she will be treated according 
to the usual standards and policies for disability” or, for example, that “no person who is unfit for work will 
be employed.” 
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Education and Prevention, VCT, Equitable Insurance 
 
HIV/AIDS Policy and Implementation 
6 Centers have made education and prevention a central tenet of 
policy, but implementation has been modest. 
8 Centers have made a firm policy commitment to VCT, but 
implementation remains spotty. 
No Center in Africa has been able to make a firm policy 
commitment to equitable insurance for NRS. 
 
The remaining pillars of HIV/AIDS policy advocated by many 
international organizations: namely, investing in HIV/AIDS 
education and prevention; encouraging employees to consider 
Voluntary Counseling and Testing (VCT); and, providing equitable 
insurance for nationally recruited staff (NRS) have not been so easily 
adopted.  
 
Table 2 provides a summary of those commitments. 
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Table 2: Policy Commitment to VCT, Education & Prevention, 
Equitable Insurance 
 
 Education &  
Prevention 
VCT Equitable Insurance 
Africa    
ICRAF Yes Yes “No” -- “we are trying to 
evaluate how to develop 
this aspect of our policy” 
IITA Not as matter of 
policy, but in active 
practice 
Yes “No” -- ‘NRS is entitled to 
equitable care but care is 
limited to poor level of in-
country inpatient care’ 
ILRI Yes Yes “We are “exploring 
opportunites” 
WARDA Yes Sound 
Practice 
“Complex issue” 
Asia    
ICLARM Yes, for employees 
and families 
Yes “No” -- ‘unfortunately in 
Asia this poses a great 
challenge’  
IRRI Yes Yes “Yes” 
IWMI No Yes “Yes” 
Latin 
America 
   
CIMMYT Not as matter of 
policy, but in 
practice 
Yes “Yes” – ‘policy assures that 
HIV/AIDS coverage will be 
available to IRS and NRS’ 
 
Table 2 shows quite clearly that many Centers feel that their ability to 
provide equitable insurance, or in some cases any coverage for 
HIV/AIDS treatment at all, is compromised by locally available 
insurance and care options.  
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IMPLEMENTATION:  EDUCATION AND PREVENTION 
HIV/AIDS Policy Implementation: Education and 
Prevention 
Education: Most Centers in developing countries have conducted 
one or more seminars on HIV/AIDS. 
Prevention: Two Centers provide condoms through lavatory 
dispensers. One Center makes condoms available through its on-
site clinic, One Center includes condoms in travel kits. 
VCT: One Center provides VCT at its on-site Clinic. One Center 
has identified a VCT Clinic and disseminated that information. 
Training: Staff training for HIV/AIDS has been limited to a few 
efforts in the area of confidentiality. 
 
Education 
Most Centers have engaged in a modest measure of HIV/AIDS 
education and prevention regardless of formal policy commitments.  A 
small number of centers are making a concerted effort. Providing basic 
HIV/AIDS awareness seminars is the most common educational 
activity.  In a number of cases, seminars have been widely inclusive 
with invitations extended to casual laborers, on-site partner 
organizations, other partner organizations and family members.  It is 
interesting to note that the level of attendance at seminars and 
workshops correlates very closely with HIV/AIDS prevalence in the 
region – seminars and workshops at Africa-based centers are said to be 
well or very well attended, while in Latin America, where HIV/AIDS 
prevalence remains relatively low, seminars have apparently been 
poorly attended.   
 
Prevention 
Condoms are not widely available to staff, but some progress is being 
made. Four Centers. CIFOR, ICRAF, ICRISAT, IITA, now make 
condoms available to staff, but only one of those centers, ICRAF, has 
made them available in both female and male lavatories.  The survey 
indicates that a number of Centers have discussed placement of 
condom dispensers, but have not determined a course of action. It is 
clear that the issue of condom provision remains a difficult and 
culturally sensitive topic, requiring each Center to exercise its best 
judgment.   
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Voluntary Counseling and Testing (VCT) 
Experience from Africa suggests that VCT is the perhaps the most 
important mechanism for successful, concentrated HIV/AIDS 
education and prevention. Only a few Centers have taken any 
significant action in this area.  Studies also suggest that when people 
receive VCT, discussion of HIV/AIDS in the workplace becomes 
more open and more positive, enabling further education, prevention 
and compassionate intervention. HIV/AIDS workplace policy, 
therefore, increasingly stresses the importance of publicizing VCT 
clinic locations and providing referrals to qualified VCT Clinics.  
WARDA has established a relationship with a VCT Clinic and referral 
information has been widely disseminated at the Center. IITA states 
that the on-site clinic in Ibadan can provide VCT while IRRI’s clinic 
at Los Banos can provide testing, but no counseling. Two other 
Centers advise that they can provide referrals to a VCT Clinic on 
request. One Center qualified its commitment to VCT expressing a 
concern about the impropriety of approaching a staff member 
regarding testing of any kind. It is precisely for this reason that referral 
information needs to be widely disseminated, making the choice be 
entirely voluntary and yet systematically encouraged.  
 
Training 
No Center has provided any staff training in the area of supervision of 
HIV/AIDS employees. Three centers, CIMMYT, ICLARM, 
WARDA, have provided some form of training in the confidential 
handling of medical information.  This contrasts sharply with UN 
agencies and the World Bank that have instituted careful 
confidentiality procedures for the management of HIV/AIDS medical 
information.  The need for training and procedures for the confidential 
management of HIV/AIDS medical information is likely to become 
more pronounced as more Centers begin to provide ARV therapy.   
 
Appendix 2 (1) provides a comparative review of education and prevention 
implementation, focusing on seminar activities, VCT, condom distribution, and staff 
training. 
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IMPLEMENTATION:  PEER COUNSELING, SAFE BLOOD, 
OCCUPATIONAL HEALTH AND SAFETY 
 
 
HIV/AIDS Policy Implementation:  Peer Counseling, Safe 
Blood, OHS 
One Center has initiated a peer counseling program. 
Two Centers provide a list of safe locations to obtain blood. 
Centers with Occupational Health and Safety Guidelines generally 
include references to HIV/AIDS. 
 
 
Only one Center (WARDA) has initiated a peer counseling program, 
although a number of centers state that some form of peer counseling 
is under consideration. It is surprising that more of the Africa-based 
Centers have not considered or developed a peer counseling program.  
Successful peer counseling programs instituted at other organizations 
of similar size have been able to achieve an openness that enables 
improved HIV/AIDS care, even where financial constraints limit what 
the organization can offer.   
 
Only two Centers have made available a list of locations where one 
might obtain safe blood, although the UNAIDS model policy considers 
this a standard element of medical information and HIV/AIDS 
prevention that should be provided to all employees.  
 
Travel kits are currently provided by only one Center (CIFOR), and 
although they provide condoms CIFOR has not decided whether to 
include post-exposure prophylaxis (PEP) kits. PEP is a complex 
treatment for exposure to HIV, and is discussed in the next section of 
the paper. 
 
Appendix 2 (2) provides a comparative review of HIV/AIDS policy 
implementation, with attention to peer counseling, safe blood location lists, 
occupational safety and health standards, including the provision of travel kits and 
PEP kits. 
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IMPACT AND INCIDENCE OF HIV/AIDS ON FUTURE HARVEST 
CENTERS  
 
Impact and Incidence of HIV/AIDS   
3 Centers, all in Africa, report “feeling the impact” of HIV/AIDS 
in the workplace.  
6 Centers report that they are “concerned about the future”.  
7 Centers report that they are “not currently experiencing the 
impact”.  
 
The survey questionnaire asked whether a Center was “feeling the 
impact of HIV/AIDS in terms of ailing employees, death of 
employees, or other HIV/AIDS related family or work stress?”  Three 
Centers, all located in Africa, reported they were “feeling the impact” 
currently, while another six Centers professed to be “concerned about 
the future.” Another seven Centers responded that “no” they were not 
currently experiencing the impact of HIV/AIDS.  Of course, these 
short answers cannot capture the intensity of the impact or the depth 
of the concern.  Conversations with directors and other staff members 
at African Centers both before and during this study, often revealed 
intense concern, heightened by the uncertainty for the future. 
 
The questionnaire went on to ask whether Centers were particularly 
concerned about staff in some regions or employment categories.  As 
expected, Centers answered overwhelmingly that they were most 
concerned for staff posted in Africa, generating the following list of 
countries of concern across the various Centers:  Ethiopia, Ghana, 
Kenya, Malawi, Rwanda, South Africa, Tanzania, Uganda, and 
Zimbabwe.  Indeed, these are all countries with double-digit rates of 
HIV prevalence.  This is a critical issue for further development of 
policy and implementation.  It is not safe to assume that location in 
Africa puts a staff member in touch with best practice on HIV/AIDS 
policy and implementation. Concern for staff posted in Africa requires 
closer attention to HIV/AIDS policy implementation, especially to 
medical coverage being provided either by host institutions or through 
other field office, program and project arrangements. We recommend 
that Centers outside Africa name an HIV/AIDS focal person with the 
responsibility to review current education and prevention activities as 
well as medical coverage being provided to Africa-based staff. 
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Estimating the incidence of HIV/AIDS at Future Harvest Centers 
proved difficult as it does in all organizations that commit to no 
HIV/AIDS testing.  In summary, most Centers based in Africa 
estimate variously that they have two-to-three, or five- to-10 
HIV/AIDS cases among those insured by the Center.  These numbers 
are based primarily on medical claims or center-based clinic 
information.  In this manner, the total estimate of HIV/AIDS cases 
across all Centers ranges from eight-to- 25.6  These are all relatively 
certain cases, and based on conversations at ICRAF and ILRI it is safe 
to assume that Centers recognize that there are certainly other AIDS 
cases still not identified through current mechanisms.  The struggle to 
improve HIV/AIDS risk assessment is discussed in the next section.   
 
Appendix 1 provides UNAIDS data on HIV prevalence for each 
country in which a Future Harvest Center is headquartered.   
INSURANCE COVERAGE FOR NATIONALLY RECRUITED STAFF 
Insurance for Nationally Recruited Staff 
Centers, in general, do not provide an enabling environment for 
HIV/AIDS care, in the form of medical, disability or life 
insurance. 
Only a few Centers in Asia and Africa provide medical schemes 
that are likely to cover the cost of HIV/AIDS treatment, even with 
greatly reduced ARV prices. 
 
The survey included an extended series of questions on existing 
insurance coverage for nationally recruited staff (NRS) in order both to 
increase understanding of the current situation for HIV/AIDS care 
and to establish a baseline for assessing whether Centers should 
consider other insurance options that offer improved care for HIV-
positive staff members.   
 
NRS in developing countries are covered under a wide variety of 
plans, almost all of which are either locally procured and/or self-
funded and many of which exclude HIV/AIDS care either explicitly 
or by virtue of plan limits.  In short, only a few Centers in Asia and 
                                                 
6 We did not include theoretical estimates based on national HIV/AIDS prevalence rates, although this is a 
useful starting point for risk assessment.  
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Africa provide insurance coverage that is likely to cover the cost of 
HIV/AIDS treatment, even at greatly reduced prices for ARVs.7 
 
All NRS at all Centers receive some form of outpatient and inpatient 
coverage with internal distinctions occurring at only three of the 
Centers.8 Patterns of coverage for employees of African and Asian 
Centers generally exhibit similarities with modest coverage limits, some 
amount of HIV/AIDS testing by local insurers and sometimes explicit 
exclusions and limitations for HIV/AIDS.  Insurance coverage for 
NRS in Latin America appears to be in a class of its own, providing 
unlimited or very high coverage, including full coverage of HIV/AIDS 
care with much of the service being extended through the National 
Health Plans, in the case of CIAT and CIMMYT. 
 
Appendix 3 (1) and C (2) contain comparative tables of outpatient and 
inpatient coverage of Centers located in developing countries. 
 
 
                                                 
7 Internationally Recruited Staff (IRS) and many Regionally Recruited Staff (RRS) at Future Harvest 
Centers are currently covered under an AETNA medical insurance plan, administered by AIARC.  As of 1 
January 2003, this medical coverage will switch to J Van Breda, a leading global insurer based in Belgium.  
HIV/AIDS is treated as a pre-existing condition in the first year of employment during which time 
coverage is limited to US$4000, as is the case with other pre-existing conditions.  After the first year of 
employment, HIV/AIDS is treated as any other medical condition and is subject to the standard limitations 
of the plan. ISNAR, IPGRI and IFPRI provide medical coverage to NRS that is either identical to or 
equivalent to that provided IRS throughout the system.  Of the seven Centers employing staff in the RRS 
category, four covered RRS under the same AETNA plan as IRS, two Centers covered RRS under the same 
plan as NRS, while one Center provided separate coverage for RRS. 
8 Distinctions occurred in two cases on the basis of wage/salary levels and in one case between urban-based 
and other staff. 
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Outpatient Coverage  
 
Outpatient Health Coverage 
Self-insurance – Approximately one-half of all Centers located in 
developing countries self-insure for outpatient coverage, providing 
Centers the freedom to determine appropriate HIV/AIDS 
coverage. 
On-site clinics – 7 Centers operate on-site clinics that, depending 
on capacity, could perform important functions in the area of 
HIV/AIDS education, prevention and care. 
 
The distinguishing feature of outpatient coverage for NRS in the 
CGIAR is the number of Centers providing outpatient care on a self-
insured basis.  Approximately one-half of all centers located in 
developing countries self-insure.  Additionally, almost one-half of the 
Centers operate a clinic on-site, managed either by a local health 
management firm under local insurance cover or by the Center itself, 
on a self-insured basis. These choices reflect the perceived 
inadequacies of local insurance coverage and/or medical care in many 
locations, a reality for which Centers have sought to compensate even 
before the additional concerns prompted by HIV/AIDS.  Self-
insurance, of course, gives the Center the freedom to provide 
HIV/AIDS care if medical services are available and they so choose9. 
 
Coverage limits for outpatient care vary from less than US$500 per 
year to “unlimited coverage,” although, on closer examination, it is 
important to note that “unlimited coverage” involves qualifications 
and sometimes significant limitations.  Even where the plan does not 
explicitly limit or even address HIV/AIDS, the median coverage limit 
for Asia and Africa-based Centers is unlikely to cover the cost of ARV 
treatment, except in those countries where generic ARVs are already 
available.  Even in those latter countries, it is worth examining whether 
current coverage limits would extend to the management of 
opportunistic infections and other HIV/AIDS related care.10  
 
                                                 
9 Only two of the Asia/Africa Centers (CIFOR and IITA) who self-insure stated that their “plan covers 
HIV/AIDS related expenses, including ARVs.”  CIFOR also advises that HIV/AIDS care is difficult to 
obtain in Indonesia due in great part to government regulations.  IITA is the only Center that appears to 
have the capacity to provide HIV/AIDS care, although ARVs in Nigeria are currently costly at a reported 
US$250.00 per month.  
10 In two of the countries where generic ARVs are available, Sri Lanka and India, the outpatient coverage 
limits of the Centers are less than US$500.00 per year. 
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On-site clinics can perform important functions in the education, 
prevention, and care for HIV/AIDS. Four Centers reported that their 
on-site doctor would be able to extend medical services for HIV/AIDS 
patients, although only three of those advised that they had access to 
ARV drugs. Other Centers were more cautious about capacity in this 
area, stating “no” the clinic is not prepared to provide HIV/AIDS 
care.  Confidence in the clinic’s ability to provide HIV/AIDS care 
should be examined with caution.  HIV/AIDS medical care is 
considered to be a special area of expertise and in some countries 
physicians must be specially licensed to provide anti-retroviral therapy.  
With regard to VTC, Centers need to ascertain whether the clinic can 
provide the requisite pre-test and post-test counseling that must 
accompany testing. 
 
Inpatient Coverage 
 
Inpatient Health Coverage  
More than half of all inpatient and hospitalization plans are subject 
to HIV/AIDS restrictions.  
Many local insurers require HIV/AIDS testing. 
 
Like outpatient care, inpatient health plans are highly varied across 
Centers.  Centers are less likely to self-insure for inpatient care, seeking 
external insurance to cover the less predictable risks associated with 
hospitalization.  More than half of these plans are subject to 
restrictions for HIV/AIDS.  Many local insurers require HIV/AIDS 
testing at th time of employment. The ability of many Centers to 
extend HIV/AIDS care in hospital is severely compromised. 
 
Appendix 3 (2)) provides further details. 
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Cost of Medical Coverage 
 
Costs of Health Care Coverage 
Reported costs of medical coverage for Centers located in developing 
countries range from less than US$300 per NRS employee per year to 
US$1,250 per NRS employee per year. 
  
The cost to the Centers of medical care provided to NRS was not 
easily determined using survey responses. Most Centers reported that 
data was not available or that it would be provided at a later date.  
This is understandable, as medical costs for NRS are often a complex 
combination of local insurance, self-insurance, on-campus clinic 
expenses and very different arrangements for inpatient and outpatient 
coverage.  For those few Centers able to report the total cost of NRS 
medical care, the range ran from less than US$300 to approximately 
US$1,250 per employee per year, with African Centers generally at 
the low end of the range.11  In this case, the contrast with the cost of 
medical insurance at IFPRI, ISNAR and IPGRI is instructive with 
IFPRI spending over US$1,000,000 on total health expenses, more 
than US$6,000 per employee12, while IPGRI pays over US$2,000 per 
nationally recruited employee.  The immediate implication is that 
international insurance coverage schemes for NRS modeled on that of 
IRS would almost certainly be considered prohibitively expensive by 
the Centers.  Fortunately, there may be intermediate options that 
allow for improved HIV/AIDS care. These options will be discussed at 
greater length in the final section of the paper. 
 
 
Disability and Life Insurance 
 
Staff Disability and Life Insurance 
Almost all Centers provide some disability and life insurance for 
nationally recruited staff. 
About one-third of disability and life insurance providers require an 
HIV/AIDS test. 
About one-third of disability and life insurance providers will not pay a 
claim if the individual is disabled by or dies of AIDS. 
                                                 
11 We suspect, although no data was made available, that the current medical expenditures at some Asian 
Centers are also low as reflected in the very low coverage limits under self-insured plans. 
12 It was unclear whether the US$1,000,000 figure included IRS and NRS, or just NRS – therefore the 
US$6000 is an approximate figure. 
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Life insurance and disability insurance are essential components of 
HIV/AIDS employee care.  As phrased by an AIDS insurance 
advocate: 
 
“Health insurance gets you access to medical treatment how 
and when you need it, disability insurance helps to cushion 
the devastating financial blows if you become unable to work 
and lose your income, and life insurance promises to help 
smooth the financial path of those you love in the event of 
your death.”13 
 
Almost all Centers, 78 percent, provide some form of disability 
insurance, and all Centers provide some life insurance.  However, at a 
number of Centers neither life insurers nor disability insurers will pay 
benefits if the client is known or even presumed to have HIV/AIDS. 
Aside from any financial loss, this has other very negative effects. It 
acts as a major deterrent to improved HIV/AIDS care and 
communication.  Employees fear that if they learn their HIV status 
and/or reveal their HIV positive status to medical insurers, that they 
will jeopardize payment under disability or life insurance plans.  As 
there has been little hope of extended life through medical treatment, 
most HIV-positive employees choose to remain silent about their 
condition and work as long as possible, hoping to maintain access to 
disability benefits and life insurance payments.    
 
Most insurers requiring an HIVAIDS test report those results to 
Centers and some, not all, insurers refuse to extend a contract if the 
test is positive.  Most organizations as well as many doctors conspire 
with patients to avoid noting the cause of death or disability as 
HIV/AIDS on insurance documentation.  Even if a life insurer pays a 
claim, some organizations now attach the payment to reduce 
outstanding hospital bills so often associated with an AIDS death, 
thereby further compromising the capacity of the family to carry on 
after his or her death.  
 
The concerns about medical coverage for HIV/AIDS have 
overshadowed concern for life and disability insurance coverage.  
Many Centers responded that that they did not know if an insurer 
                                                 
13 See Paul Hampton Crockett. ”Your Insurers are Not Necessarily Your Friends.” Retrieved from 
http://www.thebody.com/crocektt/insurers.html. 9 September 2002. 
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would pay a claim in the event of an AIDS death or disability.  These 
Centers are strongly encouraged to investigate this issue. If it is 
determined that an insurer would not pay, alternatives should be 
explored. Development NGOs working in refugee and war zones, for 
example, must already self-insure for death and disability benefits and 
are able to extend those benefits in the case of HIV/AIDS.  The study 
did not undertake an extended investigation of alternative options. 
 
Appendix 4 offers a comparative review of life and disability insurance issues at 
Future Harvest Centers. 
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 Lessons from the Kenya Case Study 
 
At the time the CGIAR Gender & Diversity Program began this study 
in April 2002, Future Harvest Centers in Kenya, ICRAF and ILRI, 
were wrestling with a number of immediate HIV/AIDS concerns.  
Indeed, the experience of ILRI and ICRAF were formative in the 
design of the survey.  It was decided that undertaking a case study in 
Kenya would help us bring to light the realities of adapting 
HIV/AIDS policy to local circumstances.  The goal was to find 
answers to practical questions of implementation -- How might ILRI 
and ICRAF gain access to ARVs? Would it be possible to get logistical 
assistance from the World Bank or the UN? Is it true that no local 
insurers provide HIV/AIDS coverage? Are there other methods for 
insurance coverage that could be tested in the Kenya context? Is there 
good local HIV/AIDS data, or are there local consultants that can 
help assess risk for HIV/AIDS? 
 
Additionally, Kenya is host to a large number of donor agencies and 
development NGOs. It is headquarters for the United Nations 
Environment Program (UNEP) and Habitat, home of a World Bank 
mission, and the regional base for many other UN agencies. Thus, 
Kenya offers an opportunity to learn how other organizations are 
dealing with these same issues.  It is the combination of visits to other 
organizations, local insurance agents, doctors’ offices, and interviews at 
ILRI and ICRAF that constitute the “Kenya case study.” 
 
The Kenya case study prompted discoveries in a number of areas.  An 
important lesson from the study is that the world of HIV/AIDS 
workplace policy is evolving very rapidly.  Organizations that were just 
beginning to look at HIV/AIDS issues at the onset of this study in 
April 2002 are now considering HIV/AIDS treatment programs.  
Some insurance firms are responding, albeit modestly, to the reality of 
HIV/AIDS in their marketplace. International research organizations 
are building evidence for pro-active care.  The pace of change is 
palpable.  
 
Some of the case study details are unique to Kenya and East Africa, 
but in the process links have been made to critical issues of HIV/AIDS 
care with implications far outside the region.  Undertaking this case 
21 
study provided a valuable opportunity to investigate the 
implementation of the World Bank and UN models for HIV/AIDS 
care that have been upheld as models of best practice. 
 
The case study focuses on several issues of importance to the Future 
Harvest Centers:  costs and access to ARVs, the costs and benefits of 
investment in ARV therapy, assessment of HIV/AIDS risk in 
organizations, and the response of other organizations to the 
inadequacies of local insurance coverage for HIV/AIDS.  In addition 
during the course of the study, interesting information emerged about 
issues of confidentiality and post-exposure prophylaxis. 
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ANTI-RETROVIRAL THERAPY:  OPPORTUNITY, OPTION, 
OBLIGATION  
HIV/AIDS Treatment 
Anti-retroviral therapy for HIV/AIDS employees is now a very 
real option for Future Harvest Centers. 
Many Centers as well as field offices are located in countries with 
reduced-cost and/or generic ARVs. 
Centers must decide what changes to medical schemes are 
required to make ARV therapy a reality for NRS. 
 
In 2001, when the G&D Program presented a model for workplace 
policy, the cost of treatment for people living with HIV/AIDS was 
perceived by many organizations as prohibitive.  Since that time, the 
costs of anti-retroviral drugs (ARVs) -- the chief component of effective 
HIV/AIDS treatment – have fallen dramatically.  In Kenya, a “triple 
cocktail” of ARVs now costs approximately US$85 per month, which 
is less than one-quarter of what it cost one year ago.  Similar 
reductions have occurred in other low and middle-income countries 
through the reduced price offers of leading pharmaceutical companies. 
14  
 
The greatest reduction in prices, however, has occurred in those 
countries that are producing or importing generics.  Thus, in Uganda 
where generics are available, ARVs can be purchased at about one-
half or less of the price of the equivalent non-generic (“originator”) 
drugs in neighboring Kenya.  Medecins Sans Frontieres one of the chief 
advocates for access to essential medicines in developing countries, 
recently published a paper trying to provide organizations with 
updated information on sample prices for low- and middle- income 
countries.15  They conclude, along with a number of other advocacy 
groups, that the lack of transparency continues to hinder access to 
                                                 
14 Global public pressure led to a partnership between the UN and five pharmaceuticals in May 2000 called 
the “Accelerating Access Initiative.”  Following the announcement of the partnership, these five companies 
announced their intention to cut the prices of ARVs, although the price cuts were not clearly specified.  The 
result has been a series of bilateral negotiations and a wide range of reduced prices around the world. Other 
pharmaceuticals have since joined the inititative. 
15 Medecins Sans Frontieres (June 2002). Untangling the web of Price Reductions:  a Pricing Guide for the 
Purchase of ARVs for Developing Countries.  Retrieved from http://www.acccessmed-msg.org. 
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essential medicines.16  Still, it is safe to say that many of the countries 
in which Future Harvest Centers operate in the developing world now 
have access to reduced-price ARVs and some countries, India and Sri 
Lanka, have access to locally or regionally-produced generics.   
 
HIV/AIDS treatment has three primary components: (1) prophylactic 
treatment of some opportunistic infections with antibiotics and other 
drugs, (2) the direct treatment of opportunistic infections, and (3) anti-
retroviral therapy as well as the associated lab tests, check-ups and 
medical management of side-effects. Anti-retroviral therapy or, more 
precisely, highly active anti-retroviral therapy (HAART) 17 consists of 
the administration of a “triple cocktail” of life-extending drugs.  To 
date HAART remains the only treatment that can lead to a substantial 
extension of life for people living with HIV/AIDS (PLWHA).  In the 
absence of ARVs, their disease progresses rapidly. With HAART, they 
can lead productive lives for 10 to 15 years, or perhaps many more.  
 
The sample costs for HAART in Kenya provided through a full 
service HIV/AIDS clinic are currently as follows: 
 
                                                 
16 Few Centers were able to provide much information on the availability or cost of ARVs in their 
respective countries, with the qualified exception of centers in South Asia who are aware of the availability 
of generics in the region and therefore can assume that the prices are among the lowest in the world.  
17 HAART refers to a regimen of multiple ARVs, consisting of precise combinations of protease inhibitors 
(PI), non-nucleoside reverse transcriptase inhibitors (NNRI) and nucleoside analogue reverse transcriptase 
inhibitors (NRTI) that make up the so-called “triple cocktail.” 
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Table 3: Costs of Anti-retroviral Therapy (HAART) at a Clinic in 
Nairobi 
 
 Units 
Cost Per 
Unit 
Ksh. 
Cost Per 
Unit 
US$ 
Costs per 
Year 
US$ 
Stage 1:  HIV+ CD4>200     
Program Consultation Sessions 4 3,000.00 38.46 153.85 
Lab Test – CD4 Count 4 2,500.00 32.05 128.21 
Lab Test – Viral Load 2 8,000.00 102.56 205.13 
Total Stage 1 Costs18:    $ 487.18 
     
Stage 2:  HIV+ CD4<200     
Program Consultation Sessions 8 4,000.00 51.28 410.26 
Lab Test - CD4 Count 4 2,000.00 25.64 102.56 
Lab Test - Viral Load 3 8,000.00 102.56 307.69 
Lab Test  - Amylase 4 800.00 10.26 41.03 
Lab Test - Serum Creatinine 4 350.00 4.49 17.95 
Lab – Hemogram 4 670.00 8.59 34.36 
CXR 1 700.00 8.97 8.97 
Stage 2: Diagnostic & 
Monitoring    $ 922.82 
Stage 2a: First Line 
Antiretroviral Month 6,500.00 83.33 1,000.00 
Stage2b: approx. 50% require 
Combvir Month 7,700.00 98.72 1,184.62 
Avg. of those requiring 
Combvir and not    $  1,092.31 
Total Average Stage 2 Costs:    $  2,015.13 
 
 
                                                 
18This does not include the cost of antibiotics or other drugs used in Stage 1 to treat or prevent opportunistic 
infections.  As ARV therapy is introduced in Stage 2 the cost of other drugs usually declines as 
opportunistic infections decline. 
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Although the ARVs, lab tests and consultation costs are based on 
Kenya prices, the example in Table 8 illustrates the size of a healthcare 
package required to provide HAART. ARVs in Kenya are now 
available for between US$80 and US$100 per month, but the 
accompanying lab tests, check-ups and medical treatment of side-
effects approximately doubles the monthly costs of Stage 2 HIV/AIDS 
care.19  
 
Specialized HIV/AIDS medical care also requires associated services 
such as psychological and nutritional counseling, and systematic efforts 
by practitioners to ensure compliance. Compliance is essential for 
patient health, but also to reduce the threat of drug resistance.  As 
ARVs are more widely administered around the world, many 
observers and researchers fear increasing HIV resistance to common 
ARVs.  Fear of drug resistance is not widely accepted as an excuse for 
not offering HAART, but fear of drug resistance is a good reason to 
search for the best local medical services.  
 
Because of recent reductions in price, a number of organizations in 
Kenya are just starting to pay for ARVs.20  Some are proceeding on an 
ad hoc basis, but some have established careful policy guidelines.  As 
these organizations sort out the rapidly changing options in Kenya and 
in the other countries in which they operate, the pattern of coverage 
still varies considerably.  One organization will pay for staff members 
only; one pays for staff and spouse, but not other dependents; one pays 
only in countries where generic drugs are available, thus excluding 
Kenyan staff, and so on. Some organizations specify minimum 
laboratory facilities or minimum care standards that must be in place 
before a HAART program is initiated. Such statements are sometimes 
attached to other “minimum standards of care” that more centralized 
NGOs and donor agencies specify for country program insurance and 
medical schemes. 
 
Appendix 5 contains a statement that accompanied the introduction of 
ARV therapy in one development NGO. 
                                                 
19 We explored with a local doctor what the cost of ARVs would be if a patient appeared independently 
requesting ARV care.  In that case if accessed by prescription through private physician and purchased at 
one of the only four or five pharmacies now providing ARVs the cost could be as much as 30% to 40% 
higher.  We assume, but did not ascertain that lab costs would also be substantially higher if individually 
procured.  
20 We did not extend the Kenya case study to private sector firms.  From secondary sources, we learned that 
a number of private firms in Kenya are now also beginning to provide HAART.  Some firms such as 
Tetrapak have actively publicized the fact that they now provide HAART. 
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Among donors, DFID21, for example, provides HIV/AIDS care to 
nationally recruited staff around the world subject to the following 
broad provisos: 
That coverage is limited to those countries where there is 
no local state scheme to which staff could turn for 
treatment; 
That the necessary medical infrastructure is available to 
enable full treatment to be administered effectively; 
That treatment is limited to employee and long term 
partner only; dependants are not covered; 
That the right to treatment lasts only as long as 
employment does (though with special provision for those 
who leave through retirement/retrenchment rather than as 
a result of their own actions);  
That all new recruits be required to show that they are 
medically fit for work  (DFID does not permit or require 
HIV/AIDS testing for employees at the time of 
employment or at any other time) 
 
Many organizations currently are piloting HIV/AIDS treatment 
programs and policies and expect to make revisions and add countries 
to their coverage lists in the near future. As would be expected, most 
organizations limit coverage to the period of employment.  Only one 
organization in this study has put forward a guarantee of ARV 
treatment for life.  This generous offer is being piloted by that 
development NGO in Burundi where the government has recently 
made important strides in the HIV/AIDS policy area including the 
provision of generic ARVs and careful licensing of HIV/AIDS 
practitioners.  It is increasingly common to find employers now 
providing ARVs to HIV-positive pregnant women in the effort to 
prevent mother-to-child transmission22.  This last is a low-cost 
                                                 
21The US State Department, in contrast, has been a latecomer to HIV/AIDS workplace policy putting 
forward a minimalist workplace policy for “national employees and U.S. citizen resident local hires” only 
in August 2001. The US State Department does not cover ARVs for national staff living with HIV/AIDS. 
The policy “allows” overseas missions to negotiate with local insurance carriers for long-term medications 
for the suppression of opportunistic infections and brief course of anti-retroviral drugs only to prevent 
mother-to-child transmission.  See “New Policy on HIV in the Workplace” retrieved, September 2002, 
from http://www.state.gov/r/pa/prs/ps/2001/4603.htm  
22 Nevirapene, an ARV, has been found to be effective in blocking mother-to-child transmission of HIV in 
at least 60 percent of the cases in African studies. The mother receives a dose just prior to giving birth and 
the newborn a syrup of the medicine soon after birth.  This regimen of Nevirapene is now available for as 
little as US$4.00 in many countries in sub-Saharan Africa.  
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commitment that can make a significant impact on the next 
generation. 
 
In contrast to the UN and the World Bank, many NGOs have 
allocated considerable staff time to a careful search for the least 
expensive sources for ARVs and other HIV/AIDS services in the area.  
Indeed, one of the sad realities of HIV/AIDS care in Kenya is the 
pressing need to manage the costs for the terminally ill.  One NGO 
insists that those employees accessing the recently established 
HIV/AIDS reserve fund seek terminal care at less expensive hospitals 
rather than the leading hospitals covered under regular insurance.  
 
In conclusion, HIV/AIDS treatment is now readily and professionally 
available in Kenya at a cost of approximately US$500 (Stage 1) and 
US$2000 (Stage 2) per employee per year, with the expectation that 
these costs will continue to decline.23 Although, we cannot provide 
similar information for other countries, many countries in which 
Future Harvest Centers operate have also been the recipients of 
reduced-price drug offers from pharmaceuticals. At these prices, this 
can no longer be easily dismissed as “unaffordable.”  HAART is now a 
real option in many countries and Centers must consider what changes 
to medical schemes will be required to make this option a reality.24  
 
INVESTING IN HIV/AIDS TREATMENT:  COSTS AND BENEFITS 
HIV/AIDS Treatment as an Investment 
Financial benefits in reduced absenteeism, employee retention, and 
productivity are gained as the health of employees improves. 
Investment in ARV therapy is immediately beneficial for organizations 
already paying for other medical care, including hospitalization, of 
HIV/AIDS patients.  Human benefits of improved and extended life 
for PLWHA are incalculable. 
 
 
                                                 
23 These estimates do not include the cost of drugs for opportunistic infections, which are likely to remain 
high in Stage 1 before ARVs are introduced. 
24 Such care may already be a reality at IITA where self-insurance is designed to allow for full HIV/AIDS 
treatment and where the clinic appears to be aware of the number of HIV/AIDS patients being served.   
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There is no longer serious doubt that some investment in HIV/AIDS 
prevention, education and care has not only ethical and moral value, 
but also financial benefits in the workplace.  The greater the impact of 
HIV/AIDS in a region or an industry, the more compelling the case 
becomes for action.  
 
Our interest in this topic was encouraged by very compelling data 
obtained from a health management firm in Kenya.25  This health 
management firm with operations in Kenya, Zimbabwe, and Malawi 
offered the following data from a client file. 
 
 
 
 
 
As chronicled in the diagram above, the number of occupied bed days 
(OBD) in hospital fell dramatically from approximately 120 
days/quarter to less than 10 days/quarter for those patients diagnosed 
(DX) with HIV/AIDS, following active intervention in HIV/AIDS 
care, including HAART begun in the third quarter of 2001.  The 
second diagram below also provides an impressive record of the 
associated drop in inpatient costs (as well as outpatient costs) following 
the introduction of HAART. 
 
                                                 
25 The firm, in this case, is Strategis Health.  The managing director in Kenya, Dr. Len Heffner, provided 
enormous insight into HIV/AIDS treatment.  While this data must be treated with caution as it reflects the 
experience of only one firm, it is still instructive.    
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Various questions were asked to ascertain whether the dramatic drop 
in costs (in Kenyan Shillings) and OBD were not an artifact of a move 
from hospitalization to in-home care in the terminal stages of AIDS, 
and that the reduction in cost could indeed be credited to HAART.  
Follow-up discussions confirmed that the reduction in cost could, in 
large part, be attributed to HAART.26   
 
This information goes beyond the issue of cost.  The diagrams tell the 
story of 12 people dying of AIDS.  In the third quarter of last year, 
they began to receive HAART. Eleven of the original 12 continue on 
ARVs and are fully functional, living well with HIV/AIDS.27  One 
very senior member of staff in this company well into Stage 2 AIDS at 
the time HAART began, is reported to be traveling again on a regular 
basis.  An additional seven members of this medical scheme are being 
carefully monitored and will begin on HAART as necessary.  They too 
                                                 
26 Occupied Bed Days (OBD) in the third quarter are attributable to the death of a HIV/AIDS baby whose 
parents did not seek care for the infant under the HIV program. One of the original 12 was “non-compliant 
despite intense counseling and resorted to traditional healing, dying at home without benefit of in-home 
care.   
27 UN clinic staff in Nairobi report similar stories of remarkable recovery and generally improved health 
and self-care as employees begin a regimen of HAART. 
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are living with a hope of healing, not available to them a short while 
ago. 
 
This health management firm concludes that if an organization is 
already picking up the costs of medications and hospitalization 
associated with opportunistic infections and AIDS death, then the 
organization is likely to be immediately, better off financially with an 
introduction of HAART.  If the insurance provider and/or the firm 
have been denying claims and care on the basis of HIV status, silently 
allowing or encouraging employees to leave the firm as they fall 
increasingly ill from HIV/AIDS then beginning an assertive 
HIV/AIDS care program with HAART will likely raise the 
organization’s immediate medical costs.  Neither of these calculations 
takes into account the substantial financial benefits of reduced 
absenteeism, employee retention and productivity gained as the health 
of employees is restored. 
 
Many studies are seeking to verify the financial costs and benefits of 
HAART and other HIV/AIDS interventions.   International research 
has depended heavily on the data emerging from very large mining 
companies in South Africa and Botswana, which allow for easier 
statistical verification.  One of the leading studies emerging from that 
data set is being conducted at the Center for International Health at 
Boston University.  The authors conclude in a recent paper that: 
 
 “Under reasonable assumptions about the costs and 
effectiveness of specific interventions, these firms will be 
better off financially with interventions than without.  
However better information on the effectiveness of 
interventions is urgently need to strengthen the analysis.”28  
 
                                                 
28 J L Simon, S B Rosen et al. from Research of the AIDS Economic Team, Center for International Health, 
Boston University.  This statement retrieved from 
http://www.brook.edu/dybdocroot/comm/ConferenceReport/cr09.htm 
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A number of smaller studies have depended more heavily on single 
case studies or case study comparisons of smaller firms.  These studies 
too are developing evidence that organizations are financially better off 
by engaging in active HIV/AIDS education and prevention and care, 
including provision of HAART.29,30  
 
Improved financial calculation of both direct and indirect costs and 
benefits are being developed in a number of studies.  An early and very 
frequently cited study in this area (AIDSCAP/Family Health 
International 1996) concluded that health care costs were a relatively 
small share, only 12% of AIDS-related costs while HIV absenteeism 
(37%), AIDS Absenteeism (15%), Recruitment Costs (10%), Training 
(7%), Labor Turnover (5%), Funeral Attendance (3%), Burial/Death 
Benefits Costs (10%) and Productivity Loss after Training (1%) 
accounted for the far larger share of AIDS-related costs.  Although this 
calculation requires updating to account for the greater use of reduced 
price ARVs since 1996, it continues to be cited regularly because it is 
assumed that the broad parameters of the conclusion still hold:  i.e., 
the cost of medical care is low in comparison to the total of indirect 
costs associated with HIV/AIDS, at least when HIV prevalence rates 
begin to approach double digits.  
 
In summary, the evidence is building strongly in favor of the financial 
benefits of intervention in HIV/AIDS, through education, prevention 
and HAART.  The vital benefits in terms of improved and extended 
human life are incalculable. 
 
                                                 
29 See Forsythe, Steven, Charlotte Laurence, John Stover, Jill Bausch, Joe Deering, Karen Foreit (July 
2002). “Cost Saving and affordability of antiretroviral therapy for private sector employees in developing 
countries” AIDS 2002 Barcelona XIV International AIDS Conference.  Abstract (TuORG1245) and 
presentation retrieved from http://www.aids2002.com/Program. 
30 See, also, SP Eholie, E Bissagnene, A Gaumon, J Mambo, J Guiza, A Kakou, A Kadia (July 2002). “The 
Socio-economic impact of HIV/AIDS infection and of investment in antiretroviral therapies (ARVs) on a 
private company of Abidjan, Cote d’Ivoire. AIDS 2002 Barcelona XIV International AIDS Conference.  
Abstract (MoOrB1096) and presentation retrieved from http://www.aids2002.com/Program. 
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ASSESSING RISK:  LOOKING FOR NUMBERS NOT NAMES 
 
Risk Assessment for HIV/AIDS 
No Centers have formally assessed future AIDS risk. 
Centers need to assess HIV/AIDS risk more carefully, through 
improved internal analysis and attention to the issue. 
Centers without scientific risk assessment data available must accept 
crude estimates in order to move forward on treatment and insurance 
decisions. 
 
 
Only one Future Harvest Center reported on an assessment of 
HIV/AIDS risk that appears to have been a cursory estimate of HIV 
prevalence at the Center, not future AIDS risk.  No other Centers 
reported formal mechanisms for HIV/AIDS risk assessment nor did 
any of the NGOs visited in Kenya in the course of this study.  Indeed, 
assessing risk is very difficult in all organizations that make a 
commitment not to test for HIV/AIDS31.   
 
Various international organizations engaged in similar studies were 
contacted and asked if they had developed risk assessment methods.  
They had not. No other development NGOs or development 
consultancy firms reported undertaking a formal risk assessment. The 
World Bank and the United Nations in Nairobi were not aware of any 
such models used by headquarters, nor had they done such an 
assessment locally.  In exploring whether any local firms offered 
HIV/AIDS risk assessment, medical insurers reported that “yes” such 
firms existed but that none to date had developed a sound reputation.  
As to how most medical insurers assess HIV/AIDS risk, most appear 
to assume that national prevalence rates are sufficiently high to exclude 
HIV/AIDS coverage without further analysis. Finally, by tracking the 
phrase “HIV/AIDS risk assessment in the workplace” 32 and multiple 
                                                 
31 Some HIV/AIDS consultants in Kenya have advocated use of voluntary anonymous prevalence surveys 
using saliva tests that while not sufficiently accurate for clinical purposes, are reasonably robust across 
large groups.  This is the method that has been used in mining and other large companies in southern 
Africa.  This requires that employees trust that results would indeed be anonymous. 
32 We did learn of an epidemiological method called “back calculation” that allows one to estimate from the 
number of AIDS deaths in a population “back” to the rate of HIV prevalence in that population and then in 
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variations, thereof, on the WWW, it was found primarily, and not 
surprisingly, that the inability to assess risk is a major 
deterrent to provision of HIV/AIDS medical care. 
 
How then to proceed?  National statistics on HIV/AIDS in Kenya are 
readily available and widely disseminated. HIV/AIDS data in Kenya, 
as in most of sub-Saharan Africa, is based primarily on tests performed 
among pregnant women attending antenatal clinics that have been 
selected as sentinel surveillance sites.  While these methods are thought 
to provide highly reliable figures at the national level and have proved 
remarkably robust in predicting the gender distribution of HIV/AIDS, 
these data do not allow characterization of HIV/AIDS across socio-
economic classes. Socio-economic data, if available, might allow 
organizations to estimate the rate of HIV/AIDS among different 
education classes or employment groupings.  No such data proved to 
be readily available or reliable. 33 
 
Most organizations rely, therefore, on a crude assessment of risk 
assuming that the organization shares the same HIV prevalence profile 
as the nation.  On this basis, most organizations in Kenya assume that 
15 percent of their employees are HIV-positive and some smaller 
number of those employees will have AIDS. How these numbers will 
grow over time is generally not calculated, most organizations assume 
simply that these numbers will grow. 34   Additionally, a number of 
organizations seem to have chosen a simpler course of action, reducing 
financial risk rather than trying to estimate it more closely.  These 
organizations reduce risk by limiting newer treatment programs 
(HAART) to immediate employees only or to employees in particular 
countries.  As information develops, they may choose to extend 
HAART coverage. 
 
Anecdotal evidence on the number of HIV/AIDS cases proved 
remarkably consistent across organizations.  Those organizations that 
                                                                                                                                                 
turn predict the number of future HIV/AIDS illnesses, or if HIV prevalence rates are known the same 
method allows the prediction of the number of HIV/AIDS illnesses anticipated over a given time period.  
The data required for this method proved too extensive at the organizational level and we found no other 
evidence that these formulas have been adjusted for risk estimation at the firm or organizational level. 
33 Suggestions at set-up for the study that the medical association in Kenya or various employers 
associations had developed socio-economic based statistics proved false. 
34 Knowledgeable HR personnel are aware that the incubation period is approximately seven years from 
infection to onset of AIDS-related diseases and without ARV treatment eight-to-12 years from infection to 
death.  However, at the organizational level no one appears to have modeled rates of disease development. 
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do not test for HIV/AIDS and have not provided permanent or 
consistent HIV/AIDS care become aware of AIDS cases as employees 
fall ill in Stage 1 HIV/AIDS.  In those organizations, the number of 
identified HIV/AIDS cases in the total insured population appears to 
be about 1 to 2 percent of the employee population.  Where there is an 
active program for treatment of HIV/AIDS including ARVs and/or a 
strong peer counseling program, as is the case at the United Nations, 
the number of known cases among staff and dependents appears to 
approach 5 percent of the employee population.  
 
The experience of Strategis Health35 in Kenya is broadly consistent 
with those organizational estimates.  Across their current client base, 
they find that they seem to be providing ARV treatment to about 5 to 
6 percent of the insured population presumed to be HIV-positive.  The 
rough calculation emerging from that experience suggests the following 
method: 
 
Assume that the insured population shares the national 
HIV/AIDS profile, which in Kenya implies that 15% of the 
insured population is HIV-positive.  Assume then that 
approximately 5 to 6 percent of that number will come 
forward for HAART, while another 3 percent of that number 
will be in Stage 1 AIDS, not yet requiring HAART. 
 
The medical claims officer or HR person most closely involved with 
medical claims processing proved repeatedly to be the person most 
likely to have a handle on the number of HIV/AIDS cases in an 
organization.  These individuals have learned to detect when a case is 
likely to be an HIV/AIDS case even before insurers begin to reject the 
claims, or in the case of self-insurance before the individual begins to 
exceed plan limits.  This information was often not shared with HR 
management. It was surprising that human resource managers were 
not in closer contact with these individuals, who proved to be very 
savvy about HIV/AIDS in the organization.  HR staff members are 
privy to other indications of HIV/AIDS status in the rejections of life 
insurance and disability insurance contracts in some cases.  No 
confidentiality needs to be breached if HR managers explore these 
estimates on the basis of numbers not names.   
                                                 
35 Strategis Health is the health management firm discussed earlier, now providing a full HIV/AIDS care 
package for self-insured clients.  As one of the very few firms engaged in active HIV/AIDS care across a 
growing client base, they proved to be a valuable source for estimating HIV/AIDS risk.  
35 
 
In the absence of well-developed methods for HIV/AIDS risk 
assessment at the organizational level, Centers may have to accept 
rough, even crude, estimates in order to move forward on HIV/AIDS 
treatment and insurance decisions. Fear and uncertainty of the 
financial risk should not be allowed to delay action any longer. For 
purposes, of further risk analysis we recommend close examination of 
internal medical records with the HR staff member most closely linked 
to the medical claims process and the use of a formula similar to the 
one presented above.  Iteration between these two efforts should allow 
a better estimate of HIV/AIDS risk than is currently being used at 
most Centers.  
CONFIDENTIALITY MANAGEMENT 
 
Confidentiality Management 
Centers should continue to commit to the highest standards of 
confidentiality and develop systematic procedures that protect the 
identity and dignity of PLWHA.  
Centers should invest further in VCT, peer counseling and 
HIV/AIDS treatment in a manner that will encourage PLWHA to 
come forward.  
 
Virtually all organizations that make a commitment to HIV/AIDS 
management uphold confidentiality as a central tenet of HIV/AIDS 
workplace policy.  Future Harvest Centers, UN agencies, the World 
Bank and NGOs in Kenya all voiced strong commitments to 
confidentiality.  At the UN, strict procedures on the confidential 
handling of medical information have been issued and disseminated.  
In other organizations, commitment to confidentiality protection is not 
always matched by systems development and training.   
 
With or without good systems, most organizations and HR managers 
have interpreted confidentiality very strictly and are deeply reluctant to 
approach an employee regarding his or her HIV status.  This remains 
the case even when the individual is obviously suffering and when the 
HR manager or clinic nurse is aware or deeply concerned that the 
individual has AIDS.  This type of story was repeated frequently and 
the commitment to silence was, for the most part, not challenged. Still 
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as the study proceeded we began to hear some subtle shifts. 
Compassionate employers who have confidentiality procedures in 
place, substantive and consistent care to offer HIV-positive employees 
and who have no intent to discriminate, were beginning to wonder if 
employees might be better off if they could be approached more 
directly regarding their HIV status. It is thought by other observers 
that as HAART is made available, more individuals will come forward 
and such direct approaches will become less necessary.  This is a 
complex issue, but one that Centers should remain aware of as they 
balance confidentiality with the need to encourage increased voluntary 
testing and counseling. 
POST-EXPOSURE PROPHYLAXIS (PEP) 
 
 
Post-Exposure Prophylaxis 
Centers and all field offices should identify a local source of PEP 
and a medical professional qualified to administer it.  
 
Post-exposure Prophylaxis (PEP) treatment is an emergency treatment 
for individuals who may have been accidentally or violently exposed to 
HIV through contact with infected blood or rape.  The treatment 
consists of a regimen of high-dosage antiviral medications, laboratory 
tests and counseling.36 The United Nations and the World Bank are 
committed to the provision of PEP kits as a part of an active 
HIV/AIDS workplace policy.  UNAIDS and the World Bank jointly 
produced a lengthy protocol for the importation and provision of such 
kits at UN stations around the world37.  On the ground in Kenya, UN 
clinic staff report that to date none of these kits have been used in 
Nairobi, and are regularly replaced as they expire.  Indeed, UN clinic 
staff report that they would advise employees to access PEP through 
either Nairobi Hospital or Aga Khan Hospital where such kits are also 
                                                 
36 Treatment ideally starts 1 to 2 hours after exposure, but may start as late as 72 hours, and normally lasts 4 
weeks. It must be administered under careful medical supervision as the high dosage of prophylactic ARVs 
can cause very serious side effects. Approximately 40% of health care workers that begin PEP (following 
an accidental exposure) discontinue use due to side effects according to “Post Exposure Prophylaxis” 2000 
AIDS.ORG INC. retrieved from http://immunet.org/FactSheeets/154-pep.html. 
37 This protocol is published at the UNAIDS website under “PEP Kits.” Retrieved from 
http://www.unaids.org/hivaidsinfo/UNWorkplace/Web%20version/Improving-pep.html 
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readily available and the full counseling and medical services that must 
accompany it can be provided.   
 
Other organizations have been more reluctant to make a policy 
commitment on the provision of PEP kits. One development NGO 
concerned about staff exposure to HIV in the refugee camps and war 
zones in which they operate, examined the issue carefully. After a 
lengthy study of the issue this organization extended the following 
recommendations: 
We do not advocate for or against this treatment (PEP) in 
cases of exposure to HIV.  The appropriateness of any 
treatment should be discussed between the affected 
individual and their doctor. The physician is the one 
qualified to make a recommendation in specific cases.  
However, if the use of PEP is indicated and the treatment 
agreed upon by the employee and their physician, it is 
important to begin treatment as soon as possible.  
Therefore, we are asking country programs to identify a 
source of PEP and a medical professional qualified to treat 
it. 
 (The organization) discourages country programs from 
purchasing PEP to ensure its availability due to its limited 
shelf life.  While the country program may purchase PEP 
only when the availability of the drugs in an emergency is 
in question.  In these cases it must be held in a local 
hospital, clinic or doctor’s office.  Under no circumstance 
should it be held in the office or private residence of an 
employee. 
PEP must only be used on the advice and under the 
supervision of a qualified medical professional. 
 
This recommendation that “country programs identify a source of 
PEP” and qualified medical professionals for its administration would 
seem to be good practice for Future Harvest Centers as well.  This 
example is also included to illustrate the manner in which other highly 
decentralized organizations suggest action at the country level. 
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APPROACHES TO MEDICAL COVERAGE IN OTHER 
ORGANIZATIONS 
HIV/AIDS Medical Coverage 
United Nations and World Bank provide country staff with 
medical insurance that covers the cost of ARV therapy and other 
HIV/AIDS care. 
Like Future Harvest Centers, development NGOs and some 
donors usually rely on local insurance coverage and self-insured 
mechanisms to deliver acceptable, but not always high, standards 
of care to country staff. 
Development NGOs and donors have begun to develop 
HIV/AIDS reserve funds to assist PLWHA and to begin covering 
ARV costs. 
 
The United Nations and the World Bank are regularly upheld as 
international standard-bearers on HIV/AIDS workplace policy. The 
particular feature of these policies that is applauded is the “provision of 
medical insurance for national staff equivalent to that of international 
staff.”  While precise equivalence was difficult to determine, it is indeed 
true in Kenya that the World Bank provides its “country staff”38 with 
insurance that covers the cost of anti-retroviral therapy and other 
HIV/AIDS care.  Likewise it is true that the United Nations provides 
medical coverage for HIV/AIDS care to its national and/or general 
service staff. 
 
The World Bank through its Medical Benefits Plan (MBP) offers 
insurance to country staff through a contributory scheme based on 
salary and family size, resulting anywhere from a premium 
contribution of 0.6% to 1.6% of salary depending on the number of 
dependents covered.  All insurance claims from the field are processed 
through the World Bank in Washington, D.C. with special precautions 
to protect the confidentiality of HIV/AIDS patients.   A similar plan is 
provided to a number of UN agencies, including UNEP, Habitat, 
UNICEF, and UNON in Nairobi via a self-insured mechanism called 
the Medical Insurance Plan (MIP) that is administered from the 
United Nations in New York39. Both of these plans require a 20% co-
                                                 
38 Country staff is essentially equivalent to NRS in the CGIAR. 
39 In this UN plan, employees also make a premium contribution between 1.0% and 2.25% of salary; as 
well as a 20% co-payment on outpatient services.  Plan ceilings are determined by formula based on UN 
salary structure. 
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payment as is usual for all international insurance coverage. Both of 
these schemes permit staff to access ARVs through private physicians 
in Nairobi and offer support through medical advisory services – an 
HIV/AIDS medical specialist at the World Bank and through the on-
site clinic services at the UN.  We were unable to determine from 
either of these organizations the precise cost of these programs, but 
were able to very roughly estimate costs for the institution and the 
employee at sample salary levels.  
 
Appendix 7 provides a rough estimate of the institutional and 
employee contributions at particular salary levels under these two 
plans.   
 
The patterns of medical coverage for national staff of NGOs in Kenya 
as well as many commercial firms were much closer to the medical 
schemes currently being provided by ICRAF and ILRI.  These are 
systems based on the norms of local insurance and with small 
exceptions are schemes with a very large number of exclusions, 
relatively low coverage limits and based on full reimbursement to the 
employee.  Many organizations, like ICRAF self-insure for outpatient 
coverage to compensate for the high level of exclusions that is common 
to local insurance40.  
 
Notably, within the past year almost every NGO that we had visited 
had established or was considering the creation of a special reserve 
fund to cover HIV/AIDS expenses.  The calculations for establishing 
such funds were almost entirely ad hoc and included such simple 
mechanisms as a quick build-up of funds through a corporate 
contribution of approximately US$6.00 per employee per month for a 
period of three months, an additional 10% overheard charge to 
programs and projects, and a reserve fund calculated as 10% of the 
regular medical budget. The adequacy of these reserve funds to cover 
future HIV/AIDS expenses was calculated only in a very rough 
fashion and at least one of them appeared patently inadequate.  These 
efforts, nonetheless, act as a strong foundation for a program of on-
going support in an environment of continuing risk assessment. 
 
 
                                                 
40 ILRI partially self-insures. 
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Insurance Options 
 
HIV/AIDS Insurance Options: Rough Estimations of Cost 
-- Local Self-Insurance designed to cover HIV/AIDS treatment is the 
least expensive option for Centers, but does not otherwise improve 
overall medical care for NRS.  
-- Regional Pooling through an international insurance firm is likely to 
cost from US$82 to US$124 per employee per month for a family of 
four. 
-- International insurance coverage modeled on the UN and World 
Bank medical plans is likely to cost from US$75 to US$115 per 
employee per month. 
 
Medical coverage continues to be the single greatest HIV/AIDS 
implementation challenge experienced by Future Harvest Centers. 
Centers were asked in the survey if they would be interested in hearing 
about other insurance options and most Centers responded that they 
would “assuming prices are not prohibitive.”   
 
As with virtually all issues in HIV/AIDS care, rapid change and 
development are underway in some parts of the insurance industry.  
Six months ago in Kenya, local organizations insisted with absolute 
certainty that no medical insurance firm in Kenya provided insurance 
coverage for HIV/AIDS. But during the completion of this report in 
the last weeks of September 2002, one leading insurance agency in 
East Africa, AAR, agreed to extend HIV/AIDS coverage, including 
provision of ARVs to employees at one organization for an additional 
US$40 per employee per year.41  Similarly, Strategis Health, has 
entered the market with full health management services including 
intensive HIV/AIDS care for self-insured clients. A number of newer 
regional providers based out of South Africa have been entering the 
market aggressively.  J. Van Breda, a major international insurance 
company, offers insurance for East African clients that limits 
HIV/AIDS coverage to US$3,000 per person per year for a five-year 
period, an amount sufficient to cover HAART but not a lengthy AIDS 
hospitalization.  In contrast, an international insurance broker based in 
                                                 
41 This may or may not be readily extended to other clients. This was made possible, the informant felt 
because the account while covering only 270 people in Kenya, covers many more in Uganda and Tanzania.  
The cost of ARVs in Uganda where generic ARVs are readily available is considerably lower than in 
Kenya.  The additional US$40 premium for full HIV/AIDS care had already been successfully piloted in 
Uganda.  
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the United States reports that most international insurance firms still 
“do not want to look at HIV/AIDS in the developing world” that they 
are “quite frankly frightened of the numbers.”   The first order of 
business for Centers in Asia and Africa is to review the current 
insurance market to see if, in fact, insurance providers have not already 
responded to reduced cost of ARVs with new policies for HIV/AIDS 
treatment. 
 
There is sobering evidence of the urgent need to make decisions in this 
matter.  For example, ICRAF experienced a medical budget overrun 
of almost US$18,000 in this budget year associated with the care of  
one or two HIV/AIDS patients.  As is the case with HIV/AIDS, any 
attempt to seek reimbursement from the patient ends abruptly with the 
patient’s death. This approach to HIV/AIDS, while deeply 
compassionate is not sustainable.  Had affordable ARVs been made 
available a year ago, one of those patients might be living well with 
HIV/AIDS today.  This latter option is now abundantly possible in 
Kenya.     
 
In light of the need for Centers to have more information to make 
decisions, this study offers information on various insurance options 
from improved local coverage to international insurance on a system-
wide basis.   
 
First, a pool of 6,606 NRS (all Centers excluding IFPRI, IPGRI, 
ISNAR), or 4,736 NRS (Asia/Africa Centers) or even 3,589 NRS in 
African Centers alone, is a very large insurance pool and brokers are 
interested in talking.  However, it is difficult to get even rough quotes 
from insurance brokers without providing substantial information on 
the insured population in terms of age, gender and recent medical 
claims history.  Second, quotes from major multinational insurance 
firms for “fully insured” coverage are stratospheric in cost even if 
medical care in the United States and Canada is eliminated from the 
plan, higher even than what is currently provided to IRS of the 
CGIAR.  Moreover, many international insurance firms are unwilling 
to consider covering HIV/AIDS care in Africa. 
 
Eventually, three options were found worthy of further consideration 
within the CGIAR.  For ease of presentation, these options are 
referred to as: Local Plus, Regional Basic, and International Standard. 
Please note that these are extremely rough indications of cost and are 
42 
provided as a basis for further review, not as completed analysis.  
Details of plan coverage and limits are described and compared only in 
broad terms. Any of these options would have to be pursued in far 
greater detail and with substantially more information from the 
Centers.   
 
Local Plus 
 
This is the simplest and least costly of the three options.  In short, 
Centers maintain their local medical scheme and supplement it with 
self-insurance designed specifically to cover the local costs of 
HIV/AIDS treatment.42   
 
For Kenya, we calculate roughly that this would amount to an 
additional US$28/per insured/per year for a five-year scenario, or just 
over $2.30 per month for each insured individual.  Of course, this self-
insured amount will differ from Center to Center, based on local 
HIV/AIDS prevalence rates and associated risk as well as the local 
cost of HAART and other HIV/AIDS care.  The Center would, of 
course, need to choose an appropriate method for building up the self-
insured fund and many models are available. On this basis, Centers in 
many countries should be able to make a firm and immediate policy 
commitment to NRS that HIV/AIDS treatment will now be covered.  
 
Appendix 6 presents the HIV/AIDS risk assessment and HIV/AIDS costs that 
guided these calculations in the Kenya example.   
 
The primary advantage of this approach, after low cost, is that local 
staff will continue to file claims and receive benefits as they are 
accustomed to doing.  In Kenya, for example, staff members are 
accustomed to 100% reimbursement, and the concept of co-payments 
or even methods for co-payments have been hard to introduce.  For 
those Centers who already self-insure it would be easy to blend this 
into the current medical scheme.  On the negative side, this does little 
to improve overall medical coverage for NRS in the system.  
                                                 
42 In an alternative scenario, supplementary coverage might be pooled through system-wide self-insurance 
for HIV/AIDS.  See Appendix 8, for a solution based on central pooling for HIV/AIDS coverage across 
countries. Supplementary insurance in that case is provided at the central level. This was the alternative 
devised by Development Alternatives Inc. (DAI) after a review of local insurance policies revealed 
generally poor coverage as well as lack of coverage for HIV/AIDS.  DAI is a development consulting firm 
with 500 local employees in 49 countries 
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Regional Plus 
 
J. Van Breda, a leading global insurance firm headquartered in 
Belgium, proved to be one of the few international insurance firms able 
to talk easily about local medical costs across a wide range of countries 
and most importantly about HIV/AIDS coverage in Africa.  J. Van 
Breda was not willing to provide a quote on a regional or inter-
regional basis without further information on the insured pool and 
medical claims histories of different Centers, although they remain 
interested in further discussion.  
 
Fortunately, however, J. Van Breda had recently prepared a full 
proposal for ICRAF for the year 2003, in which premium costs were 
clearly spelled out.  We asked them if we might safely assume that 
further pooling of CGIAR employees in the Africa region or across 
Africa/Asia would serve to reduce the premium costs.  They answered 
somewhat equivocally that “the advantage of pooling does not so much 
play on the technical premium setting, but it can be important for 
premium stability as peak files can more easily be absorbed.”  They 
emphasized also that medical costs differ greatly from one country to 
another, even in Africa.  On this basis, we have assumed that J. Van 
Breda would be able to offer medical insurance on a regional or inter-
regional basis in a range 20% lower to 20% higher than what they 
have currently proposed to ICRAF.  On that basis, insurance 
premiums might be obtained in the range between: 
 
US$28.00 to $42.00 per adult per month;  
US$13.00 toUS$20.00 per child per month. 
 
or, restated  
 
US$82.00 to US$124.00 per employee per month for a family of four  
 
Importantly, this plan generally provides better medical coverage than 
is currently provided at many Centers.  Plan cover limits, in the 
ICRAF proposal, are US$8,000.00 per family for outpatient expenses 
and US$12,000.00 per family for inpatient expenses, with very few 
other limitations.  Most importantly for the purposes of this study, van 
Breda has set an HIV/AIDS limit at US$3,000 per person per year for 
a period of five consecutive years.  While this is not as desirable as 
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unlimited HIV/AIDS coverage, this amount would cover HAART in 
a number of countries at recently reduced cost of ARVs, although it 
would not cover an expensive AIDS hospitalization.  Such terms may 
be negotiable with greater regional pooling.  This plan like virtually all 
international insurance plans sets a 20% co-payment for outpatient 
expenses.  Disadvantages will emerge around the greater complexity of 
administration and the J. Van Breda’s greater distance from the local 
market. 
 
International Standard  
 
This last option is modeled on the Medical Insurance Plan (MIP) of the 
United Nations and the Medical Benefits Plan (MBP) of the World 
Bank43.  We were not able to obtain as much as information as we 
would have liked about the cost of these plans directly from the 
respective organizations, but have learned something about that style 
of plan from discussions with international brokers.  Fundamentally 
these are self-insured plans (most likely with added reinsurance to cap 
risk) and therefore HIV/AIDS coverage can be established at the level 
or within the limits the client desires.  The large insurance firms that 
typically manage such plans as “administrative services only” contracts 
bear large up-front costs in the development of the plan and as such 
are likely to be workable only on the basis of a fairly large pool of 
employees and dependents.  Such plans are likely to cost, on average, 
anywhere in the range of: 
 
US$75.00  – US$115.00 per employee per month for a family of four 
 
The averages above were suggested as a range by an international 
insurance broker, but are roughly confirmed by calculations presented 
in Appendix 7. In fact, rough calculations suggest that the UN and 
World Bank though self-administered schemes are offering coverage at 
the low end of the range, or perhaps even lower depending on 
assumptions about salary structure in the respective organizations. 
 
                                                 
43 As stated in the introduction to the MBP: “The Medical Benefits Plan (MBP) is a health plan operated by 
the World Bank Group for the benefit of its country office active staff members (and their eligible family 
members) serving at designated country offices away from Headquarters.  The purpose of the MBP is to 
assist staff members and their eligible family members in meeting the cost of certain health services, 
facilities and supplies.”  A copy of this document has been forwarded to AIARC. 
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Appendix 7 presents a sample contribution to monthly premiums by the 
employee and the institution at various salary levels according to 
information gathered by interview at UNON and as described by the 
World Bank in its MBP documentation.  
 
These medical plans are almost certainly an improvement over most 
current outpatient medical schemes at the Center level in terms of plan 
coverage.44    
 
The disadvantages will emerge around the greater complexity of 
administration and the administrator’s greater distance from the local 
market.  Both the UN and the World Bank provide substantial back-
stopping in-house for the efficient processing of claims from country 
staff to headquarters.  These administrative details as well as the costs 
would require careful examination.  Both the United Nations and the 
World Bank plans involve a contribution to premium by staff members 
based on salary and the number of dependents as well as a co-payment 
of 20% for most outpatient care.  The capacity of NRS to make 
contributions in the amount of 1.0% to 2.25% of salary (UN) and 
0.6% to 1.5% of salary (World Bank) towards medical coverage would 
also require consideration at the Center level.  
 
 
Our analysis of current medical coverage in the CGIAR concludes 
that only a few Centers provide medical schemes that are likely to 
cover the cost of HIV/AIDS treatment, even at greatly reduced prices 
for ARVs.   Centers in Latin America appear to be an exception to this 
conclusion and are therefore not likely to be interested in substantive 
change to current medical coverage schemes.  Centers in Africa, 
however, need to urgently consider these or other insurance options in 
order to improve coverage for HIV/AIDS treatment. Centers in Asia 
need to seriously review current medical plans in light of local 
HIV/AIDS care options and the growing threat of HIV/AIDS in that 
region.  All Centers must pay close attention to the coverage being 
extended by host institutions to their Africa-based staff as they cannot 
                                                 
44 Coverage limits at both the World Bank and the UN are tied to a specific “reference salary,” and in the 
case of the World Bank is limited to three times that monthly reference salary amount in a given plan year, 
yielding plan limits higher than many Center outpatient medical schemes. 
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safely assume that HIV/AIDS care is being fully managed on their 
behalf. 45    
 
The choice must, of course, be mediated both by cost and conscience.  
HIV/AIDS treatment is available at substantially reduced cost.  
Evidence is growing that that expenditure has financial benefits to the 
organization.  The insurance options presented above, while more 
costly than most current medical schemes are not prohibitively 
expensive at the lower end of those ranges. The time has come to make 
this option a reality for staff living with HIV/AIDS.   
                                                 
 45 IRRI and IITA may be among the exceptions.  IITA appears to have the capacity to provide HIV/AIDS 
treatment and no obvious restrictions in the self-insured plan appear to restrict that possibility.  IRRI’s 
medical plan also permits at least some level of HIV/AIDS treatment. IRRI staff may benefit in this matter 
from their location in the Philippines. The Philippines has been cited by UNAIDS as an example of “best 
practice.” Among other thing the AIDS Law mandates the provision of insurance to persons with 
HIV/AIDS. Good laws are not a guarantee that the rights of persons with HIV/AIDS are protected, and like 
good policy, implementation in the Philippines has not been without challenges.  CIFOR’s  outpatient plan 
does not appear to limit HAART but commentary in the survey suggests that such medical care is 
problematic nonetheless. 
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Summary of Recommendations 
 
 
All Centers must engage in an accelerated and concentrated 
effort at implementation of HIV/AIDS policy, especially 
with regard to HIV/AIDS education and prevention. 
Education and prevention must remain the cornerstone of all 
HIV/AIDS workplace policy.  Preventing a single case of HIV 
infection through education is the simplest and most cost-
effective investment that a Center can make. 
Efforts at implementation must be renewed with increased 
emphasis on VCT. 
Further consideration should be given to developing peer-
counseling programs.  
Commitment to confidentiality must be matched with 
development of systems to protect the dignity of PLWHA. 
 
All Centers are encouraged to localize HIV/AIDS Policy in 
very concrete terms with specific information provided to 
staff on: 
Location and services of vetted VCT Clinics. 
Identification of sources of ARVs and approximate current 
prices of HAART. 
Source of PEP and qualified medical practitioner to treat 
and counsel. 
Locations for safe blood. 
 
Centers in Africa urgently need to implement new medical 
schemes or supplement current plans to improve coverage 
for HIV/AIDS treatment including HAART. 
Make the option of HAART a reality for all NRS. 
Review the current insurance market to see if, in fact, 
insurance providers have not already responded to reduced 
cost of ARVs with new policies for HIV/AIDS treatment. 
Consider a self-insurance scheme to cover the cost of 
HAART. 
Consider cooperation with other Centers for improved 
medical coverage through regional pooling or international 
insurance along the lines of the World Bank and the United 
Nations medical schemes. 
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Centers in Asia need to review current medical plans in 
light of local HIV/AIDS care options and the growing threat 
of HIV/AIDS in that region. 
Make the option of HAART a reality for all NRS, before a 
crisis emerges. 
Review the current insurance market to see if, in fact, 
insurance providers have not already responded to reduced 
cost of ARVs with new policies for HIV/AIDS treatment. 
Consider a self-insurance scheme to cover the cost of 
HAART. 
Consider cooperation with other Centers for improved 
medical coverage through regional pooling or international 
insurance along the lines of the World Bank and the United 
Nations medical schemes. 
 
All Centers must pay close attention to the HIV/AIDS 
education and care being extended by host institutions to 
their Africa- and Asia-based staff as they cannot safely 
assume that HIV/AIDS care is being fully managed on their 
behalf.   
Name an HIV/AIDS focal person for Africa- and/or Asia-
based staff with the responsibility to review current 
education and prevention activities as well as medical 
coverage being provided to Africa-based staff. 
 
All Centers are encouraged to review and improve life and 
disability insurance for PLWHA. 
 
All Centers are reminded that HIV/AIDS policy 
development and implementation must remain an on-going 
process in light of the continuing changes in the 
environment for HIV/AIDS. 
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Appendix 1. Future Harvest Centers Host 
Country HIV/AIDS Adult Prevalence Rates 
 
 
CIAT Colombia 0.31%  
CIFOR Indonesia 0.05% (Note) 
CIMMYT Mexico 0.29%  
CIP Peru 0.35%  
ICARDA Syria 0.01%  
ICRISAT India 0.70%  
ICLARM Malaysia 0.42%  
ICRAF Kenya 13.95%  
IFPRI United States 0.61%  
IITA Nigeria 5.06%  
ILRI Kenya 13.95%  
 Ethiopia 10.63%  
IPGRI Italy 0.35%  
ISNAR Netherlands 0.19%  
IRRI Philippines 0.07%  
IWMI Sri Lanka 0.07%  
WARDA Cote d'Ivoire 10.76%  
 
Source:  UNAIDS, June 2000 reporting data from end 1999. 
 
(Note:  Other sources suggest much higher rates of HIV/AIDS prevalence in Indonesia.  
In particular, rapid spread of HIV among certain subpopulations and increasing reports 
of mother-to-child transmission is fueling fears of very rapid spread in the general 
population.) 
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Appendix 2 (1). HIV/AIDS Education and 
Prevention Activities 
 
 Seminar(s)/ 
Workshop(s) 
Condom 
Dispensers 
VCT 
Referral 
Confidentiality 
Procedures 
Africa     
ICRAF Yes 
Multiple  
Well attended 
 
Kenya 
Free of charge. 
Male & female 
lavatories. 
Not currently 
provided 
No staff training. 
IITA Yes 
Multiple  
Very well attended 
Widely inclusive 
Nigeria 
Free at clinic, no 
dispensers. 
VCT available 
at on-site 
clinic. 
 
ILRI Yes. - - - 
WARDA Yes 
Multiple Countries 
Multiple Topics 
Well attended 
Widely inclusive 
Policy not 
finalized. 
Relationship 
established 
and 
information is 
widely 
disseminated. 
Managers 
trained. 
Asia     
ICRISAT Yes 
Multiple Countries 
Well attended 
Widely inclusive 
Zimbabwe 
Free of charge 
In male lavatories 
Not currently 
provided 
No staff training. 
ICLARM - - Referral 
information 
available 
Head of HRU 
CIFOR Yes 
Multiple Countries 
Some well 
attended 
Dispensers not 
discussed. 
Condoms 
supplied in travel 
kits. 
Prepared to 
develop if 
need arises 
No staff training. 
IRRI - Not discussed. No plans. - 
Latin America     
CIAT Yes 
Colombia 
Poorly attended. 
Widely inclusive. 
Not discussed. No plans. No staff training. 
CIMMYT Yes 
Mexico 
Poorly attended. 
Discussed, but 
chose not to 
place condom 
dispensers 
Referral info. 
available ; 
Relationship 
established 
Yes staff training. 
CIP - - - No staff training 
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Appendix 2 (2). HIV/AIDS Education and 
Prevention Activities 
 
 Peer 
Counseling 
List 
Safe Blood 
Locations 
Occupational 
Health and Safety 
(OHS) 
Travel Kits 
Africa     
ICRAF No plans. No. No. Not 
discussed. 
IITA No plans Yes and 
Institute is 
enrolled in 
Blood Care 
Foundation 
OHS manual is 
currently being 
produced. 
No. 
ILRI     
WARDA Peer 
counselor 
identified. 
- - - 
Asia     
CIFOR No plans No 100% safe 
blood 
available 
HIV/AIDS discussed 
in OHS guidelines. 
Condoms and 
malarial 
prophylaxis 
included. 
PEP not 
decided. 
ICRISAT Under 
consideration. 
Yes HIV/AIDS discussed 
in OHS guidelines. 
Not discussed 
ICLARM - No. No OHS guidelines. Not discussed 
IRRI No plans. No. No. Not 
discussed. 
Latin 
America 
    
CIAT Under 
consideration. 
No HIV/AIDS discussed 
in OHS guidelines. 
Not 
discussed. 
CIMMYT Under 
consideration. 
Available, not 
circulated. 
No OHS guidelines 
or first aid manuals 
Discussed, 
not decided. 
CIP - No. No. - 
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Appendix 3 (1). Outpatient (OP) Coverage 
for Nationally Recruited Staff 
 
 Type of Outpatient 
Coverage 
Outpatient 
Plan Limits 
HIV/AIDS 
Testing by 
insurance 
agent 
HIV/AIDS 
Coverage 
Africa     
ICRAF Center self-insures, 
administered by HRU 
and health firm 
Between  
US$ 1001 to US$2500 
(for  staff and 3-5 
dependents0 
No (self-
insurance) 
Plan does not explicitly 
address HIV/AIDS 
IITA Center self-insures, 
administered by HRU 
Unlimited Coverage No (self-insures) Center assumes 
expenses for HIV/AIDS 
related illnesses, but 
not ARVs 
ILRI Combination of local 
and self-insurance 
Unlimited Coverage in 
Nairobi 
No Phase 1 and 2, but not 
full-blown AIDS, no 
ARVs.. ARVs covered 
up to US$260 under 
self-insured portion 
WARDA National Health Plan, 
plus supplemental local 
insurance 
_ _ _ 
Asia     
CIFOR Center self-insures, 
claims administered by 
health firm 
Unlimited Coverage No (self-
insurance) 
All HIV/AIDS related 
expenses, including 
ARVs 
ICRISAT Center self-insures, 
administered by HRU 
Less than US$500 per 
year 
No (self-insures) Plan does not explicitly 
address HIV/AIDS 
ICLARM International Insurance Between  
US$ 1001 to US$2500 
Yes, at time of 
employment 
Specifically excluded 
IRRI Local Insurance/HMO Between  
US$ 1001 to US$2500 
No Up to limit of Ph.P 
150,000 
IWMI Center self-insures, 
administered by HRU 
Less than US$500 per 
year 
No (self-insures) Plan does not explicitly 
address HIV/AIDS 
Latin 
America 
    
CIMMYT National Health Plan, 
plus supplemental local 
insurance 
Up to US$35,000 No All HIV/AIDS related 
expenses, including 
ARVs 
CIAT National Health Plan 
of the host country 
Unlimited Coverage No All HIV/AIDS related 
expenses, including 
ARVs 
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CIP Local Insurance/HMO In combination with 
inpatient plan, up to 
US$23,000 
Unsure Specifically excluded. 
Middle 
East 
    
ICARDA Local Insurance/HMO Between 
US$501 to US$1000 
No Up to US$5,000 for 
HIV/AIDS, including 
drugs 
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Appendix 3 (2). Inpatient (IP) Coverage for 
Nationally Recruited Staff 
 Type of 
Inpatient 
Coverage 
Inpatient 
Plan Limits 
(per year) 
HIV/AIDS 
Testing by 
insurance 
agent 
HIV/AIDS 
Coverage 
Africa     
ICRAF Local 
Insurance/HMO 
US$25,000 Yes, at time of 
employment  
Plan specifically excludes all 
HIV/AIDS related expenses 
IITA Center self-insures, 
administered by 
HRU 
Unlimited Coverage No (self-insures) Center assumes expenses for 
HIV/AIDS related illnesses, but 
not ARVs 
ILRI Local 
Insurance/HMO 
and self-insurance 
Limit approximately 
US$6,400 per person.  
Fist US$2,565 covered 
by plan, remaining 50% 
ILRI, 50% staff 
No Phase 1 and 2, but not full-blown 
AIDS 
WARDA National Health 
Plan, plus 
supplemental local 
insurance 
_ _ _ 
Asia     
CIFOR International 
Insurance Provider 
Between  
US$ 1,001 to US$2,500 
Yes, at time of 
employment 
Plan specifically excludes all 
HIV/AIDS related expenses 
ICRISAT Center self-insures, 
administered by 
HRU 
Between  
US$ 1,001 to US$2,500 
No (self-insures) Plan does not explicitly address 
HIV/AIDS 
ICLARM International 
Insurance 
Provider 
Between  
US$ 2,501 to US$5,000 
Yes, at time of 
employment 
Plan specifically excludes all 
HIV/AIDS related expenses 
IRRI Local 
Insurance/HMO 
Between  
US$ 2,501 to US$5,000 
No Up to limit of Ph.P 150,000 
IWMI Center self-insures, 
admin-istered by 
HRU 
Between  
US$ 1,001 to US$2,500 
No (self-insures) Plan does not explicitly address 
HIV/AIDS 
Latin America     
CIAT National Health 
Plan of the host 
country 
Unlimited Coverage No  All HIV/AIDS related expenses, 
including ARVs 
CIMMYT National Health 
Plan, plus 
supplemental local 
insurance 
Up to US$35,000 per 
person per illness 
No Center assumes HIV/AIDS 
related expenses, including ARVs 
CIP Local 
Insurance/HMO 
In combination with 
inpatient plan, up to 
US$23,000 
Unsure Plan specifically excludes all 
HIV/AIDS related expenses 
Middle East     
ICARDA -  US$35,000 No All HIV/AIDS related expenses, 
including ARVs 
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Appendix 4. Disability and Life Insurance for 
Nationally Recruited Staff46 
 
 Disability 
Insurance 
Provided? 
HIV/AIDS 
Test 
Required? 
Benefit 
paid if 
disabled 
due to 
HIV/AIDS? 
Life  
Insurance 
Provided? 
HIV/AIDS 
Test 
Required? 
Benefit 
paid if 
death due 
to 
HIV/AIDS? 
Africa       
ICRAF Yes Yes No Yes, all Yes No 
IITA Special 
cases 
No - Yes, all No  Yes 
ILRI Yes No Don’t know. Yes, some At certain 
salary 
levels 
No 
Asia       
CIFOR Yes No Don’t know Yes, all Yes No 
ICRISAT Special 
cases 
No No Yes No - 
ICLARM Yes Yes No (unless 
acquired by 
blood 
transfusion) 
Yes, all Yes Yes 
IRRI Yes Yes Yes Yes, all Yes, case-
by-case 
Yes 
IWMI Yes No Don’t know Yes, all No  No 
Latin 
America 
      
CIAT Yes No Yes Yes, all No - 
CIMMYT Yes No Yes Yes, all No Yes 
CIP No Don’t 
know 
Don’t know Yes, all No Don’t know 
Middle East       
ICARDA Yes No Yes Yes No - 
 
                                                 
46 We extend our apologies to WARDA for absence of data here.  The electronic survey instrument appears 
to have pre-empted or scrambled responses to a series of questions on NRS insurance coverage in the 
middle of the survey.   
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Appendix 5. Example Pre-requisites for 
Provision of ARV 
 
The regional management office of a development NGO in East Africa issued the 
following pre-requisites for country programs considering the provision of ARV therapy.  
These stipulated: 
 
Prevention program be in place.  It is essential that prevention remain the 
mainstay of efforts to address HIV/AIDS.  All country programs should develop 
an active sensitization and education program for staff members and their 
families.  The nature of such a program may vary from country program to 
country program in order to take into consideration country specific culture and 
the status of the epidemic.  Voluntary Counselling and Testing facilities must be 
available. 
 
ARV Availability.  A variety of generic and branded ARVs are regularly 
available. … ARV treatment must be only available to those with a positive HIV 
test who fulfil the criteria for treatment. 
 
Laboratory Facilities.  The minimum laboratory tests required are 
Haemoglobin and Total White Cell Count.  Liver function tests and kidney 
function tests are desirable.  More accurate assessment of disease progression and 
when to start treatment can be made with a CD$ count.  If this is unavailable it 
means that it is likely that treatment will be started based on more clinical criteria.  
The results of later treatment are not as good but still markedly improve quality of 
life for PLWHAs.  The WHO has new guidelines for ARV treatment in resource 
poor settings, which address the issue of minimum/desirable laboratory backup 
facilities.  
 
Physicians trained in ARV therapy.  The administration of an ARV regime 
is complex and does have side effects, requires monthly physician follow-up and 
good patient compliance.  It must be carried out by someone who is adequately 
trained. 
 
Within Government Policy.  ARVs should be within the policy of the 
respective governments.  
 
 
Various assumptions are made in the background paper, including the claim that ARV 
treatment may actually reduce medical bills as fewer opportunistic infections will require 
treatment and that in East Africa HAART treatment will cost approximately US$400 per 
year per employee based on the presumption that generics are or will soon be available.   
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Appendix 6. Cost of Additional Self-
Insurance Sufficient to Cover HAART 
 
 
Example:: ICRAF 
Number of insured at Center, including hosted institutions: 728 
Adult HIV Prevalence in Kenya: 15% 
Estimated HIV+ among insured: 109 
Percent of HIV+ likely to come forward for HAART in Year 1 or 2: 5% 
Number of HIV+ individuals who are likely to enroll for HAART in Year 1 or 2: 5 
 
Scenario 1: 
Not all who are eligible come forward in the first year. 
 
Year 
Number enrolled in 
HIV/AIDS 
Program 
Cost per 
person per 
year 
Total Additional 
Costs 
Additional Cost 
Per Insured 
2003 3 $ 2,200.00 $ 6,600.00  $ 9.07  
2004 5 $ 2,200.00 $ 11,000.00  $ 15.11  
2005 7 $ 2,200.00 $ 15,400.00  $ 21.15  
2006 9 $ 2,200.00 $ 19,800.00  $ 27.20  
2007 10 $ 2,200.00 $ 22,000.00  $ 30.22  
 
Scenario 2: 
Enrollment in program begins fast. 
 
Year 
Number enrolled in 
HIV/AIDS 
Program 
Cost per 
person per 
year 
Total Additional 
Costs 
Additional Cost 
Per Insured 
2003 5 $ 2,200.00 $ 11,000.00  $ 15.11  
2004 7 $ 2,200.00 $ 15,400.00  $ 21.15  
2005 9 $ 2,200.00 $ 19,800.00  $ 27.20  
2006 11 $ 2,200.00 $ 24,200.00  $ 33.24  
2007 12 $ 2,200.00 $  26,400.00  $ 36.26  
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Scenario 3: 
Worst Case. Enrollment in program begins fast and builds fast. 
 
Year 
Number enrolled in 
HIV/AIDS 
Program 
Cost per 
person per 
year 
Total Additional 
Costs 
Additional Cost 
Per Insured 
2003 5 $ 2,200.00  $ 11,000.00   $ 15.11  
2004 8 $ 2,200.00  $ 17,600.00   $ 24.18  
2005 12 $ 2,200.00  $ 26,400.00   $ 36.26  
2006 17 $ 2,200.00  $ 37,400.00   $ 51.37  
2007 20 $ 2,200.00  $ 44,000.00   $ 60.44  
 
Additional Cost per insured averaged across five years, across all three 
scenarios: 
 
Comments and Assumptions: 
 
 (1) Costs for persons enrolled for Stage 1 HIV/AIDS management not included as many of those costs 
already being paid for. Better management at Stage 1 HIV/AIDS may even serve to reduce medications 
costs. 
 
 (2) Costs may well continue to decline as HAART provider is currently negotiating for reduced cost of lab 
reagents and some ARVs.  Expected introduction of generics in the Kenyan market will further reduce costs. 
 
(3) Staff turnover not included as conservative measure against possible underestimation of new enrollees. 
 
 
(4) Compatability between outpatient and inpatient plan must be secured but HAART is expected to 
reduce hospital costs to the extent that some HIV/AIDS hospitalization is already being paid for. 
 
(5) Not all additional costs will accrue to ICRAF, depending on arrangements with hosted institutions. 
 
(6) US$2,200 covers HAART plus some other costs, it would not cover an expensive AIDS 
hospitalization, but it is presumed that such costs will not be as common as the benefits of HAART begin 
to accrue. 
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Appendix 7. Sample Contributions by 
UN/World Bank and Employees Under MIP 
(UN) and MBP (WB) 
 
 
UNON: 
 Monthly Salary  Monthly Salary  Monthly Salary  
 $500.00  $1,000.00  $1,500.00  
 
 Employee UN Employee UN Employee UN 
Percent Contribution: 1% 9% 1.50% 9% 2.00% 9% 
Total Monthly Contribution: $5.00  $45.00  $15.00  $90.00  $30.00  $135.00  
 
UN Average contribution across three salary ranges assuming staff evenly distributed in these three 
salary classes: $ 90.00 per employee/per month 
 
 
World Bank:  
 Monthly Salary  Monthly Salary  Monthly Salary  
 $500.00  $1,000.00  $1,500.00  
 
 Employee UN Employee UN Employee UN 
 Employee WB Employee WB Employee WB 
Percent Contribution: 1.30% 3.90% 1.30% 3.90% 1.30% 3.90% 
Total Monthly Contribution: $6.50  $19.50  $13.00  $39.00  $19.50  $58.50  
 
WB Average contribution across three salary ranges assuming staff evenly distributed in these three 
salary classes: $ 39.00 per employee/per month 
 
Comments/Assumptions: 
UN:  Employee contribution can vary from 1.0% to 2.25% of salary depending on the number of dependents as well as 
salary. World Bank: Employee contribution can vary from 0.6% to 1.5% of salary depending on the number of 
dependents.UN Contribution of 9% is the approximate contribution according to UNON, proabably overstated here at 
lower levels of salary.World Bank contribution of 3.9% is as documented for employees plus three to five dependents. 
 
The accuracy of the average contribution will depend greatly on improved information on salary 
structure and numbers of personnel at different salary levels. 
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Appendix 8. DAI’s Catastrophic Health 
Assistance and Education Policy 
 
 
 
7250 Woodmont Avenue, Suite 200, Bethesda, Maryland 20814 USA 
Tel: (301) 718-8699     Fax: (301) 718-7968     Email: info@dai.com     Website: www.dai.com 
 
 
DAI’S 
Catastrophic Health Assistance and Education Policy 
Summary Sheet 
 
This policy complements the DAI HIV/AIDS Workplace Policy, released February 2002, which 
requires non-discrimination of employees affected by HIV/AIDS.  This policy outlines 
HIV/AIDS care and support services which will be available for local DAI employees worldwide.  
It also provides resources for DAI field projects to launch HIV/AIDS education and prevention 
programs for local staff. 
 
The Catastrophic Health Assistance Policy is activated when the employee’s local insurance 
and medical care coverage does not cover a catastrophic health condition such as (but not 
limited to) HIV/AIDS and related illnesses.  The above financial assistance does not apply to 
routine health maintenance. 
The policy does not require an HIV/AIDS test to qualify.  Rather, it requires at least two of 
four conditions are met: (1) inpatient hospital care; (2) a five-day absence plus treatment; (3) 
chronic condition requiring treatment; or (4) permanent or long-term conditions requiring 
supervision. 
The policy identifies a per-incident financial cap for medical treatments, services, or 
medications that are not covered through health coverage already provided by DAI. 
Employees with life-threatening illnesses may request a leave of absence (without pay) if other 
leave has been used to pursue medical care or recuperate from the effects of a life-threatening 
medical condition.   
All medical information obtained from the employee remains confidential and is handled in 
accordance with existing legal, medical, and ethical management practices. 
The policy guarantees employees’ right to work as long as they can meet acceptable 
performance standards, and as long as continued employment does not present a health or 
safety risk to themselves or to others.  
The Catastrophic Health Assistance Policy applies to actively employed DAI local employees. 
Employee spouses, children, or siblings are not eligible for financial assistance. 
DAI provides its field projects with an annual budget for a Health Education and Prevention 
Program for all staff.  In addition, DAI is providing guidance to field staff for the effective use 
of these resources. 
 
 
For more information on this policy, please contact DAI’s Office of Human Resources. 
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 Glossary  
 
AIDS.  AIDS stands for Acquired Immunodeficiency Syndrome, a disease in which the body’s 
immune system breaks down due to an infection with a virus called the Human 
Immunodeficiency Virus (HIV). 
 
ARV.  Anti-retroviral drugs. ARVs are drugs prescribed for the treatment of AIDS. 
 
CD4 count.  CD4 count is the number of CD4 cells in a cubic millimeter of blood.  
CD4 cells help to protect people from getting infections.  HIV attacks and destroys CD4 
cells.  A CD4 count in a healthy, HIV-negative adult is usually 600-1200 CD4 cells oer 
cubic millimeter of blood.  The CD4 count of most people with HIV usually falls over 
time.  If the CD4 count drops below 200, there is a high risk of serious infection and 
death.  For many developing countries, HAART is administered only when CD$ count 
falls below 200. 
 
Generic Drug.  According to the WHO, a pharmaceutical product usually intended to 
be interchangeable with the innovator (or originator) product, and which is usually 
manufactured without a license from the innovator or original patent-holder. 
 
HAART.  Highly Active Antiretroviral Therapy. HAART refers to a regimen of multiple 
ARVs, consisting of precise combinations of protease inhibitors (PI), non-nucleoside 
reverse transcriptase inhibitors (NNRI) and nucleoside analogue reverse transcriptase 
inhibitors (NRTI) that make up the so-called “triple cocktail” currently deemed the most 
effective treatment for HIV/AIDS. 
 
HIV.  HIV stands for the Human Immunodeficiency Virus (HIV) that leads to AIDS. 
 
OHS.  Occupational, Health and Safety 
 
PEP.  Post-exposure prophylaxis treatment is an emergency medical response to 
individuals who may have been exposed to the HIV.  The PEP treatment consists of 
ARV medication, laboratory tests and counseling. 
 
PLWHA.  People living with HIV/AIDS.  This is now the preferred term to use when 
discussing people who “have” HIV/AIDS.  It substitutes for earlier phrases that typically 
referred to people “suffering from HIV/AIDS” or “victims of AIDS.”  The newer term 
emphasizes the reality that with treatment people can live with HIV/AIDS. 
 
Stage 1 AIDS.  Stage 1 AIDS refers to the phase of HIV/AIDS in which the individual 
begins to succumb to illness and opportunistic infections, but is not yet thought to be a 
candidate for HAART. 
 
Stage 2 AIDS.  Stage 2 AIDS refers to the phase of HIV/AIDS in which the individual 
more frequently succumbs to serious illness and debilitating opportunistic infections.  
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Stage 2 AIDS is often identified with a CD4 count of less than 200 and where possible 
HAART is immediately indicated. 
 
 
UNAIDS. United Nations joint co-sponsored program on HIV/AIDS, created in 1996 
to lead, strengthen and support an expanded response to the HIV/AIDS epidemic.  The 
six original co-sponsors are UNICEF, UNDP, UNFPA, UNESCO, WHO and the World 
Bank. UNAIDS is the leading source for official HIV/AIDS data. 
 
Viral load.  Viral load is the amount of HIV that can be measured in the blood.  If the 
person has not developed symptoms, a viral load higher than 100,000 per milliliter of 
plasma is considered high, and below 10,000 is considered low.  A viral load assay gives 
approximately two to three months advance notice on the progress of HIV/AIDS in 
comparison to the CD4 count.  Wherever available, viral load tests are considered an 
essential part of HAART laboratory testing.  In resource poor settings, this expensive and 
often unavailable laboratory test is not considered essential.  
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